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 A cascade reaction is developed to form complex cyclopentanones using an asymmetric 
Michael/Benzoin sequence.  This reaction employs simple aliphatic aldehydes and ketoesters in 
conjunction with a chiral amine catalyst and a chiral NHC catalyst.  Further investigation reveals 
a surprising interplay between these two catalysts.  This relationship is manifested in a pseudo-
dynamic kinetic resolution, which is responsible for the high diastereoselectivity observed. 
 
 Subsequent work details the discovery of the aminomethylation of enals using NHC 
catalysis.  This reaction utilizes an iminium source as well as cinnamaldehyde derivatives to 
form gamma-amino butyrate derivatives.  Rendering this reaction asymmetric has proven a 
challenge, despite extensive effort to resolve these issues.  In the course of these studies, an 
unexpected NHC-catalyzed Morita-Baylis-Hillman reaction was observed.  Optimal conditions 
for this reaction were established, proving access to useful amino-enals. 
 
 In an effort to design suitable catalysts for the asymmetric aminomethylation reaction, a 
strategy for the late-stage manipulation of NHC catalysts was developed.  Key to this strategy is 
the ‘protection’ of the triazolium salt by reduction to the triazoline.  An aryl C-Br bond is then 
exploited for cross-coupling reactions, building a small library of new catalysts.  The triazolium 
salt is then recovered by oxidation with a trityl salt.  
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CHAPTER 1 
 




1.1  Benzoin Discovery 
 In the 1830’s, Justus von Liebig and Friedrich Wöhler undertook studies of the 
properties of bitter almond oil.1  The oil was extracted from bitter wild almonds, which 
are the highly poisonous progenitors of the modern domesticated almond.  During the 
course of their studies, they noticed formation of a new compound: benzoin (5, Figure 
1.1).  The source of this phenomenon is due to one of the key constituents of bitter 
almond oil: amygdalin (1).  This compound easily fragments to release sugars (4), 
benzaldehyde (2), and cyanide (3).  Liebig’s student, Nikolay Zinin, further studied this 
unusual reaction.  Zinin proved that the combination of benzaldehyde and only a 
catalytic amount of cyanide is needed for this reaction to proceed. 
Figure 1.1  
 In 1943, Ugai and coworkers discovered that this transformation could be 
catalyzed by a thiazolium catalyst derived from thiamine.2  Shortly after, Breslow 
proposed a mechanism for this reaction.3  This was modeled after work published by 
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stabilized N-heterocyclic carbene II (Figure 1.2).    The catalytic cycle begins with the 
nucleophilic addition of the carbene catalyst onto benzaldehyde to form intermediate III.  
Proton transfer leads to the formation of the en-diaminol IV, commonly referred to as the 
“Breslow Intermediate.”  This intermediate then adds into a second equivalent of 
benzaldehyde.  Proton transfer leads to intermediate VI, which then collapses to release 
benzoin 5 and the carbene catalyst II.   
 
Figure 1.2  
1.2 Stetter Reaction 
 The most intriguing feature of the benzoin reaction is the catalytic formation of 
the acyl anion equivalent.  Formation of a transient nucleophile from an electrophilic 
species and its associated reactions is often termed Umpolung.5  The next question was 
whether this nucleophilic intermediate can add to other electrophiles.  One of the first 

































	   3	  
an aldehyde and an enone to yield a 1,4-dicarbonyl compound using either cyanide or a 
thiazolium-based carbene as a catalyst (Scheme 1.1).6  This serves as a solution in the 
synthesis of this challenging motif. 
 
Scheme 1.1  
 A key difference between the benzoin reaction and the Stetter reaction is that the 
former is occasionally reversible while the latter is not.7  In addition, several groups 
observe that the benzoin product is often formed faster than the Stetter product, but the 
dimer is eventually consumed while the ratio of Stetter product increases.8  In certain 
instances, it is possible to use a benzoin product as a source of the acyl-anion 
precursor.9   
 
 Besides enones, Stetter showed that enoates, acrylonitriles, and several other 
Michael acceptors are competent in the reaction.10  However, he also described many 
limitations.  Substitution at the α-carbon seems to be well tolerated.  In contrast, he 
reported only limited success with β-substituted Michael acceptors.  The nature of the 
aldehyde is not as stringent, with aryl and aliphatic aldehydes shown to be suitable acyl-
anion donors.  It should be noted that the use of NHC catalysts often lead to milder 
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 The Rovis group has made a significant impact with the development of the 
asymmetric intramolecular Stetter reaction,11 based on a substrate designed by Ciganek 
(Scheme 1.2a).12  Key to the success of this reaction was the design of novel triazolium 
precatalyst 11.  Based on an aminoindanol developed at Merck,13 this catalyst maintains 
a rigid backbone that proves excellent at inducing asymmetry.  The chromanone 
product 12 is formed in both high yields and high enantioselectivity.  This initial work 
was expanded to include aldehydes with aliphatic backbones as well (Scheme 1.2b).  
Triazolium precatalyst 14 based on phenylalanine is employed in this case.    
 
Scheme 1.2  
 In addition, higher substitution on the olefin is tolerated. With β-substitution, 
products that bear an enantioenriched quaternary carbon are formed (Scheme 1.3a).14  
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Scheme 1.3  
a convenient route to this system.  Substitution at the α-carbon is also tolerated 
(Scheme 1.3b).  This motif allows formation of a second stereocenter, and this is formed 
in high diastereoselectivity.15  This high selectivity can be explained by an 
intramolecular protonation event (Scheme 1.3c).  This effectively translates chirality 
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desymmetrization of cyclohexadienones 22 (Scheme 1.3d).16  This motif allows for the 
rapid construction of three contiguous stereocenters. 
 Enders and coworkers first reported an asymmetric intermolecular Stetter 
reaction with chalcones as substrates.17  In the Rovis group, glyoxamides were pursued 
due to their success as donors as described by Stetter.18  For the electrophile, 
alkylidene malonates were selected for their high reactivity (Scheme 1.4a).   This 
reaction proved successful with the use of phenylalanine derived triazolium precatalyst 
26.19  High yields and enantioselectivity are maintained with a diversity of alkyl-
substituted malonates.  This system was later extended to alkylidene ketoamides 28 
(Scheme 1.4b).20  As the use of tertiary amides inhibits epimerization, these products 
are formed in both high enantio- and diastereoselectivity.  
 
Scheme 1.4  
 Heteroaryl aldehydes were next explored as donors for the asymmetric Stetter 
reaction with nitroalkenes as the Michael acceptor (Scheme 1.5).  Catalyst design 
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acids (26), only provided moderate selectivity.  Introduction of a fluorine in the backbone 
of catalyst 33 significantly improves selectivity.  The impact caused by this group on 
enantioselectivity while being distant from the active site of the catalyst was initially 
puzzling.  An explanation for this effect was a strong puckering of the 5-membered ring, 
which is observed by X-Ray crystallography.  This could arise from a strong 
hyperconjugation effect between an electron-rich C-H bond and the activated σ* orbital 
of the C-F bond.  Alternatively, the σ* of the C-F bond could interact and direct the ionic 
nitro moiety of the Michael acceptor.22 
 
Scheme 1.5  
 This same catalyst motif was used successfully again in the development of 
further intermolecular Stetter reactions.  New aldehyde donors include enals23 and 
aliphatic aldehydes.24  In addition, this catalyst was also employed by the Gravel group 
in the intermolecular Stetter between heteroaryl aldehydes with keto-esters.25 
  
 Glorius and coworkers have shown that unactivated alkenes26 and alkynes27 can 
make excellent electrophiles (Scheme 1.6).  Tethered alkenes and alkynes lead to 
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on the alkene.  We propose a ‘retro-Cope elimination’ is responsible for this 
transformation.  They have further developed this reaction to intermolecular variants.  
They demonstrate that cyclopropenes are excellent substrates.28  Additionally, they 
report that certain styrenes are also competent partners leading to ketone products.29 
Scheme 1.6  
1.3 Benzoin Reaction 
 There remains significant challenges associated with the benzoin reaction, 
including selectivity between homobenzoin vs cross-benzoin, reversibility of the benzoin 
reaction, and facile epimerization of the products.  Despite these issues, there has been 
considerable accomplishments in this area by several groups including Enders30 and 
Gravel.31 
 
 Suzuki and coworkers have successfully employed asymmetric intramolecular 
benzoin reactions in the synthesis of natural products.32  They utilize a modification of 
the aminoindanol scaffold pioneered by the Rovis group (not shown).33  The desired 
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 One strategy to promote cross-selectivity is to use the ‘aza-benzoin.’  This 
ultimately leads to the formation of amino-ketones selectively.  The first reports of this 
came from the López-Calahorra lab in 198834 and Merck Process in 2001.35  In 2012, 
DiRocco and Rovis reported a similar aza-benzoin using a specialized triazolium salt 42 
(Scheme 1.7a).36  Compounds were isolated in high yields and enantioselectivily.  
Iminiums are also suitable as electrophiles, and DiRocco and Rovis demonstrated  
 
Scheme 1.7  
that these could be formed catalytically through the use of photoredox catalysis 
(Scheme 1.7b).37  There are several important aspects that should be made explicit.   
First, this reaction serves as an excellent example of cooperative catalysis, with both 
catalysts working independent from each other.  There appears to be no detrimental 
effect between the NHC and the Ru(bpy)3 photosensitizer.   Second, they elucidated 
that an ‘aza-Breslow’ intermediate is formed between the iminium and NHC catalyst.38  
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acid.  Third, this remains one of the few examples of asymmetric reactions that involve 
photoredox catalysis. 
 
1.4 Redox Chemistry 
 In the 2000’s, several groups reported an unusual transformation when α-
reducible aldehydes are used as an acyl-anion donor.  Rather than seeing nucleophilic 
behavior at the aldehydic carbon (e.g. benzoin or Stetter), what is observed is an 
oxidation of the aldehyde as well as a reduction at the α-carbon.39  This unexpected 
redox pathway can be explained by multiple possible reaction pathways after the 
formation of the acyl-anion equivalent (Figure 1.3).  When a leaving group is at  
 
Figure 1.3  
the α-carbon (e.g. a chloride, epoxide), this group can be eliminated by the Breslow 
intermediate IV.  The enol equivalent generated can undergo protonation (or alkylation) 
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equivalent, and is easily displaced to release the NHC catalyst and a new ester or 
amide. 
 
 In 1873, Wallach observed this transforation with the conversion of 
trichloroacetaldehyde to a dichloroacetate using a cyanide catalyst.40  This remains the 
earliest example of this type of mechanism (Scheme 1.8). 
Scheme 1.8  
 Using a chiral NHC catalyst, the Rovis group was successful in eliminating a 
single chloride from a dichlorinated aldehyde (Scheme 1.9).  The chiral enolate 
equivalent then protonates stereoselectively, and after displacement of the catalyst by 
water, provides enantioenriched α-chloro-acids.41   
 
Scheme 1.9  
 In addition, the Breslow intermediate formed from enals can impart nucleophilicity 
at the β-carbon, often called an “extended Breslow” Intermediate (V in Figure 1.3).  
Following a similar pathway as before, an ester equivalent can easily be formed.  This 
strategy can allow for the formation of enantioenriched α-fluoro amides as demonstrated 
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Scheme 1.10  
 Rovis and coworkers further used this chemistry to form γ-lactams in high 
enantioselectivity and diastereoselectivity from enals and imines (Scheme 1.11).43  
Scheidt and coworkers reported a similar transformation, but arrive at the alternate 
diastereomer.44  Zhao and Rovis noticed the use of achiral NHC 58 and chiral 
carboxylate base 59 can impart moderate enantioselectivity.  The chiral acid formed in 
this reaction can activate the imine, thus leading to this stereoselectivity.   
 
Scheme 1.11  
 Similar to work done with chloro-aldehydes, enals can form chiral enolate 
equivalents after protonation.  Whereas we had previously catalyzed an asymmetric 
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employed this strategy for the formation of delta-lactones.45  Rovis and coworkers 
applied this methodology to the synthesis of δ-lactams (Scheme 1.12).46   
Scheme 1.12  
 Recent work by White and Rovis describes the homoenolate addition of enals 
with nitroolefins to form acyclic systems.47  A more in-depth explanation of this area will 
be found in Chapter 3. 
 
 Hopefully this introduction has provided a brief insight into recent advances with 
NHC-based organocatalysis.  The key feature of this chemistry is the inversion of 
polarity of electrophilic aldehydes.  Through catalyst development, a myriad of new 
chemical transformations have been uncovered, including reactivity at both the 
aldehydic carbon and β-carbon.  The following chapters will further describe several 
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CHAPTER 2 
ASYMMETRIC MICHAEL/BENZOIN CASCADE FOR THE SYNTHESIS OF 




2.1 Introduction to Cascade Reactions 
 Of all the catalysts that our group has designed and created, the most utilized are 
the catalysts bearing an N-pentafluorophenyl group.48  The impact of this highly 
electron-deficient substituent can be explained by its pKa.49  The acidity of the C-H bond 
of the triazolium is increased, meaning that it can be deprotonated by a weak base.  
This leads to a higher proportion of active catalyst available.  Additionally, it is our belief 
this leads to an increased acidity of the NHC-aldehyde adduct.  This translates to easy 
and facile formation of the requisite Breslow intermediate with weak bases (see Chapter 
1).50  While this can lead to highly efficient reactions, there is another attribute that is 
often overlooked.  The ability for NHC-catalysis to exist under mild conditions can allow 
for other synthetic transformations to occur.  The best example for this strategy is 
cascade catalysis. 
 While there are many competing names for this process (e.g. cascade, domino, 
tandem), we define cascade catalysis as a reaction containing two or more independent 
catalytic cycles.51  This strategy has been popular in recent years for its many 
advantages.  By combining multiple catalytic processes in one flask, one can generate 
elaborate and complicated compounds from simple starting materials.    Cascade 
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reactions avoid extra workups and purification, which not only conserves time and 
resources, but also is essential if an intermediate is unstable to isolation.  As such, there 
are many excellent examples of this work in the literature.52 
 Our group grew interested in using NHC catalysts in cascade reactions.  There 
has been some precedent that this is feasible, such as the work of Hamada53 and 
Glorius54 combining NHC and Pd catalysis (Scheme 2.1).  In addition, Glorius has 
provided an example with NHC and base catalysis.55  There are also examples of 
cascade reactions where the NHC is responsible for multiple transformations.56  We 
focused our research on the synthesis of enantioenriched compounds using 
NHC/organocatalysis cascade reactions. 
 
Scheme 2.1  
 Stephen Lathrop reported our initial finding.  He discovered a cascade reaction 
that combines asymmetric iminium catalysis with a diastereoselective benzoin 
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1,3-dicarbonyl nucleophile 2 (Scheme 2.2).  This occurs via formation of an iminium 
intermediate from the amine catalyst and the enal.  This activated species undergoes 
conjugate addition from the acetyl-acetate derivative.  Release of the amine catalyst 
provides aldehyde intermediate 6.  This aldehyde is intercepted by the NHC catalyst 
and undergoes a benzoin cyclization with the ketone to form a cyclopentanone. 
 
Scheme 2.2 
There are two important attributes that should be mentioned.  Lathrop showed that 
sodium acetate is an effective base.  This is useful, as the acetic acid generated as a 
byproduct is important for turnover of the amine catalyst.  However, acetic acid has also 
shown to be excellent as a useful additive for NHC catalysis and has since become 
commonly found in recent reports.58   
 
 The second observation is that this is a ‘one-pot’ reaction.  In cascade reactions 
reported by other groups, it is common for the second catalyst to be added later.59  
Sometimes there is a solvent exchange as well.  Lathrop’s reaction is interesting in that 
not only can this cascade be run with all reagents present, but also that it must be run 
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(the ‘two-pot’ reaction), Lathrop observes a diminished yield and diastereoselectivity 
(Scheme 2.3).  Unexpectedly, he noticed a significant drop in enantioselectivity.  To 
investigate this phenomenon, he conducted mechanistic studies.  The result of this work 
indicates that the first step of the reaction, the conjugate addition, is reversible.  The 
benzoin cyclization quickly consumes this intermediate, preventing complete 
racemization.  
Scheme 2.3 
 The next question to consider was if other modes of organocatalysis are 
compatible with NHC’s.  The use of base catalysis between salicylaldehyde and 
propiolates can lead to an intermediate that is suitable for an intramolecular Stetter 
reaction.  Claire Filloux studied and developed this reaction, leading to an elegant 
reaction system (Scheme 2.4).60  This reaction forms enantioenriched benzofuranones 
10 from salicylaldehydes (7) and electron-deficient alkynes (8).  She employs either 
quinuclidine or DABCO as a base catalyst and chiral triazolium 9 as an NHC source.  
This process not only allows for the asymmetric formation of benzofuranones, but also 
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Scheme 2.4 
 There are some features worth mentioning regarding Filloux’s work.  Besides 
alkynes, she demonstrated that allenes are suitable surrogates.  Additionaly, she 
conducted a ‘two-pot’ reaction, similar to Lathrop’s work.  In these experiments, Filloux 
noticed a drop in yield from this study (Scheme 2.5).   
 
Scheme 2.5 
After further investigation, she determined that the salicylaldehyde starting material also 
functions as an additive for the Stetter reaction, most likely from the phenol moiety.  In 
fact, she improves the reaction significantly when catechol 15,61 also containing a 
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 Lathrop reasoned that an intermediate similar to aldehyde 6 in his earlier work 
can be obtained using enamine chemistry rather than iminium catalysis.  He drew 
inspiration from work published by Ma and coworkers.62  They reported an asymmetric 
addition of aliphatic aldehydes to activated enones using chiral amine catalyst 18 
(Scheme 2.6).  After a reductive workup and silylation, they isolate keto-alcohol 
products in high enantio- and diastereoselectivity.  Their initial product (20), before 
reduction by sodium borohydride, bears the same backbone as the intermediate seen in 
Lathrop’s work.  In theory, interception of this intermediate by benzoin cyclization would 




2.2 Reaction Development 
 A new project was started to determine if this pathway was feasible.  As a safe 
approach, we initially reproduced Ma’s protocol and added the NHC catalyst and base 
later.  While formation of the desired intermediate was smooth, the benzoin reaction did 
not proceed (Scheme 2.7a).  Upon suggestion by coworkers, the solvent was switched 
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fortuitous, as we were able to isolate the desired compound (Scheme 2.7b).  This initial 
hit was very exciting, as the compound was generated in high enantioselectivity, 
moderate diastereoselectivity, and in modest yield.  However, we were delighted that 
there is no detriment with the inclusion NHC pre-catalyst 4 from the outset of the 
reaction, making this a ‘one-step, one-pot’ reaction.  It was decided to focus on 
improving the yield of the reaction (Scheme 2.7c). 
 
Scheme 2.7 
 Different bases were then screened in an effort to increase the yield of the 
reaction.  While several bases were completely ineffective, several matched the 
capability of sodium acetate (Table 2.1).  These include amine bases such as 
triethylamine, N,N-diisopropylethylamine, and N-methylmorpholine.  There is also a 
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showing increased yields.  However, these results were far below expectations, so more 
options to improve the reaction was explored.  
Table 2.1 
 
 There was concern that perhaps the initial step of the reaction, the amine-
catalyzed conjugate addition of the aldehyde with the enone, was responsible for the 
poor results.  Literature has shown that a catechol additive can lead to significantly 
improved results in this type of reaction.63  In fact, our group has shown that catechol 
derivatives are superb additives for various NHC-catalyzed transformations.13a  
Catechol derivative 15 developed by Chi and Gellman was therefore employed in this 
reaction.13b  We observe dramatic improvements in yield when an achiral NHC catalyst 
is used, especially with sodium acetate as base (Scheme 2.8b).  Thrilled with this result, 
this reaction was carried out with chiral NHC catalyst 9.  Exceptional diastereoselectivity 
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Scheme 2.8 
 Following advice by my colleague Phillip Wheeler, this reaction was run under 
heated conditions.  By heating this reaction to 60 ºC, high conversion to the desired 
product is achieved (Scheme 2.9a).  We were delighted that high enantioselectivty is 
maintained (94% ee).  However, diastereoselectivity remains poor, with a ratio of 9:2.  
This is resolved when a chiral NHC is used, resulting in a 19:1 dr (Scheme 2.9b).  This 
is accomplished without any loss in enantioselectivity or yield.  Choice of NHC catalyst 
is crucial though.  A bulkier aryl group leads to even higher diastereoselectivity.  The 
antipode of the catalyst leads to a 4:1 dr, and a separate chiral scaffold provides similar 
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Scheme 2.9 
 With heat as a useful additive in this reaction, a base screen was revisited.  
Bases that gave similar results to sodium acetate at room temperature also provide 
superb results at the elevated temperature (Scheme 2.10).  Other carboxylate bases are 
also advantageous in improving the diastereoselectivity, whereas the amine base 
(diisopropylethylamine) forms product in lower yield.  We also tested the reaction 
without a carboxylate base, with the hypothesis that the amine catalyst is also capable 
of deprotonating the triazolium salt.  Not only is this true, but it is accompanied by a 
dramatic improvement in diastereoselectivity, with the product formed in a 66:1 dr with 






















































































































	   24	  
Scheme 2.10 
 The proposed mechanism is shown in Figure 2.1.  Condensation of the amine 
catalyst 18 with butanal 16 forms the reactive enamine I.  This then undergoes Michael 
addition with the enone 17 to form II.  Hydrolysis of the iminium releases the amine 
catalyst and the aldehyde intermediate 20.  This aldehyde is intercepted by the NHC 
catalyst and forms the requisite Breslow  
Figure 2.1 
intermediate III.  This then adds onto the tethered ketone to form the cyclized 
intermediate IV.  Proton transfers, followed by ejection of the NHC catalyst, forms the 
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2.3 Scope of Reaction64 
 With suitable conditions that provide high yield, diastereoselectivity, and 
enantioselectivity, it was deemed prudent to explore the scope of this reaction.  
Variation of the aldehyde donor was initially explored (Table 2.2).  Similar to butanal, 
other straight-chain aldehydes are suitable substrates (21b-c).  Isovaleraldehyde, which 
bears a branched group, lead to complications.  Notably, formation of Stetter product 
was observed.65  We inferred that the first catalytic  
Table 2.2 
 
cycle might have been slowed by this bulkier aldehyde.  By withholding the triazolium 
salt until complete consumption of starting materials (monitored by TLC), the desired 
cyclopentanone is formed (21d).   Larger aldehydes are also tolerated, but in lower 
yields and diastereoselectivity (21e-g). 
 Variation of the enone was then explored (Table 2.3).  Replacing the ethyl ester 
moiety with a methyl ester was successful (21h).  The benzyl ester is also competent, 
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are well tolerated (21j-k).  While diastereoselectivity is moderate (about 9:1 dr), 
enantioselectivity is superb.  We also explored variation of the ketone group.  Both 
ethyl- and propyl- ketones can be used in this reaction (21l-m).  The bulkier isopropyl-
ketone does not provide product with our standard conditions (21n).  However, when 
the smaller achiral catalyst 4 is employed, formation of the desired cyclopentanone is 
achieved.  A phenyl-ketone group is also effective, in good yield and enantioselectivity 
but in lower diastereoselectivity (21o).    Diketones are also competent, albeit in lower 
yields and stereoselectivity (21p-q).  This is likely due to their higher reactivity, and side 
reactions are more prevalent with these systems.  In the case of an unsymmetrical 
diketone, only one regioisomer is formed for compound.  This indicates that the 
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 We were curious if further transformations can be affected onto this system.  One 
key feature of these compounds is the α-hydroxy-ketone.  This system is an excellent 
substrate for a directed reduction of the carbonyl.  Treatment of this compound with 
sodium triacetoxyborohydride in acetonitrile at room temperature provides the expected 
trans-diol 25 (Scheme 2.11).  Luckily, this product can be obtained in ‘one-pot.’  After 
complete formation of cyclopentanone is observed by TLC, the reaction is cooled to 
room temperature.  Addition of acetonitrile and sodium triacetoxyborohydride provides 
the diol product in 84% yield, 88% ee, and a 40:1 dr.   
 
Scheme 2.11 
 Absolute configuration was determined by X-ray crystallography.  The ester of 
the cyclopentanone product 21i was hydrogenated to the free acid, and the ammonium 
salt was generated from a chiral phenethylamine.  This salt was recrystallized from ethyl 
acetate.  The relationship of the alcohol and alkyl groups was determined from this 










































2.4  Mechanistic Insight 
 As mentioned earlier, Lathrop and Filloux noticed an astonishing requirement for 
both catalytic cycles to be present to achieve their excellent results.  Their ‘one-pot’ 
protocol was essential for success.  We were curious if this relationship was present in 
this reaction as well.  To explore, the first catalytic cycle was conducted in absence of 
the triazolium salt.  The intermediate aldehyde 20 was isolated in low dr (often between 
1:1 to 3:1 dr).  This aldehyde was then exposed to the triazolium salt and acetate base 
(Scheme 2.12).  The expected cyclopentanone was isolated in similar yield and 
enantioselectivity to products from the ‘one-pot’ protocol.  This contrasts to what was 
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diastereoselectivity (4:1 dr instead of 19:1 dr).  Intriguing as this is, we conducted further 
experiments.  The benzoin catalytic cycle was repeated again, but with the amine 
catalyst also added.  This combination improves the diastereoselectivity to 10:1 
(Scheme 2.12c).  The chirality of the amine is not even essential: the use of pyrrolidine 
(27) in place of the chiral catalyst increased the dr to 20:1 (Scheme 2.12d).  However, 
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 These results were quite unexpected.  A dramatic improvement in 
diastereoselectivity is observed when a chiral NHC is used instead of an achiral catalyst 
(see Scheme 2.9).  This naturally led to the belief that the high diastereoselectivity is 
formed during the benzoin cyclization, catalyzed by the chiral NHC catalyst.  However, 
these ‘two-pot’ experiments seem to refute this hypothesis.  There also seems to be an 
essential role for the amine catalyst in the second catalyst.  This seems contradictory, 
as the amine catalyzed reaction provides the intermediate aldehyde 20 in low dr, but is 
somehow responsible for the high dr of the finished compound. 
 We proposed several different hypotheses to explain these findings.  One 
experiment provided useful insight and guidance for our investigation.  When the 
aldehyde intermediate is exposed to the amine catalyst in the presence of deuterated 
methanol, complete deuteration is seen at the α-carbon of the aldehyde (Scheme 2.13).  
It should be noted that this experiment is flawed, as a methanolic environment is highly 
different from the regular reaction conditions. 
 
Scheme 2.13 
 Nevertheless, this observation led us to consider this carbon as the center for the 
diastereoselectivity.  With this as a basis, we proposed a new catalytic model for this 
reaction (Scheme 2.14).  We assume that the benzoin cyclization is slow while the 
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epimerizes the α-carbon of the intermediate aldehyde quickly as well.  One 
diastereomer of this aldehyde (20a) is then favored for the benzoin cyclization.  The 
unfavored diastereomer is then converted to the favorable one by this epimerization. 
 
Scheme 2.14 
 While this proposal was interesting, more evidence was needed beyond the 
deuteration experiment.  Following the suggestions of my colleagues Harit Vora and 
Todd Hyster, this reaction was monitored by 1H NMR.  For the sake of simplification, we 
focused on the transformation of the aldehyde intermediate to product.  This 
intermediate was isolated in low diastereoselectivity (3:1).  Monitoring the entire spectra 
would be prohibitively complicated, so attention was paid solely to the consumption of 
the aldehyde peaks.  First, the intermediate aldehyde was combined with the triazolium 
salt and sodium acetate in deuterated chlorform at 60 °C.  NMR spectroscopy clearly 
































































A second experiment was conducted which combined the aldehyde intermediate with 
both catalysts and sodium acetate (Fig 2.4).  In contrast to the previous experiment, 
signals from both diastereomers persist in the reaction.  It also appears that both 
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Figure 2.4 
Lastly, the amine catalyst is added to the reaction mixture of the first NMR experiment 
(Fig 2.5).  While one aldehyde diastereomer was completely consumed in this 
experiment, addition of the amine leads to the reemergence of both diastereomers.  
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Figure 2.5 
 This relationship can be considered a pseudo-‘Dynamic Kinetic Resolution 
(DKR).’  A true DKR converts a racemic mixture of starting material to one enantiomer 
of product.  Normally, a DKR reaction has to differentiate between two enantiomers of 
equal energy.  Our reaction selects between two possible diastereomers, which are 
inherently of different energy.  Exposure of a cyclopentanone formed in low 
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no improvement.  This indicates that the final step of this reaction is irreversible.  Thus, 
the diastereoselectivity observed is from a kinetic process, not a thermodynamic one. 
 With the correct structure and mechanism determined, we sought to rationalize 
the observed stereochemistry.  The stereochemistry α to the ester is explained by the 
chiral amine catalyst, and so this must translate to the selectivity for the next two 
stereocenters.  We also deduced that the α-carbon selectivity is formed between the 
first and second catalytic cycle, and is dependent on the structure of the NHC catalyst.  
Previous work in our group has demonstrated the importance of internal ‘proton shuttles’ 
for NHC catalysis.66  Often, this is a heteroatom found in the substrate that aids in 
deprotonation to form the Breslow intermediate.  We were curious if a carbonyl in the 
intermediate can also serve this role.  This intermediate has two carbonyls as potential 
proton shuttles: the ester and the ketone.  A transition state with the ketone as proton 
shuttle has the two substituents in an anti conformations, as what is seen in the product 
(I, Fig. 2.6).  This seven-membered transition state also orients the carbonyl oxygen at a 
larger angle, optimal for deprotonation of the pre-Breslow intermediate.  This theory can 
explain the observed configuration. 
 
Figure 2.6 
However, this model lacks any explanation for the influence of catalyst structure in 
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rationale for the observed selectivity.  For example, it is still unknown if either NHC 
addition into the aldehyde or formation of the Breslow intermediate is reversible. 
 With the mechanism more clearly understood, we were curious if there is a 
strategy to ‘tune’ the stereoselectivity.  Our idea was with proper choice of NHC catalyst, 
another diastereomer could be favored.  A perfect example of this is demonstrated by 
Carreira and coworkers.67  The right combination of a chiral amine catalyst with a chiral 
Ir catalyst allows specific access to one of four isomers.  I initially explored the use of 
the antipode of the successful catalyst, but this led only to a diminished diastereomeric 
ratio, and not an inverted one.  Another chiral scaffolds also failed to show any inversion 
of this intermediate. 
 
2.5 Applications Toward the Synthesis of Natural Products. 
 Complex cyclopentanes are a motif found in many biologically active molecules 
(Fig 2.7).  For example, the cores of marine natural products massadine68 and 
palau’amine69 bear a fully substituted cyclopentane.  Both these compounds share an 
elaborated cyclopentane core, with 5-contiguous stereocenters.  They also possess a 
unique sp3 C-Cl bond that is not common in many alkaloids.  Cyclopentanes are also 
present in several terrestial-based natural products.  This includes Crescentin IV, a 
small natural product isolated from the Calabash tree.70  Even though it lacks significant 
bioactivity, it is most likely a precursor to several other iridoid products that are 
medicinally interesting.   
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Figure 2.7 
The syntheses of massadine, palau’amine, and similar compounds have elicited a fair 
amount of attention from the synthetic community.  Much of the work has been in the 
construction of the densely substituted cyclopentane core.  We were curious if our 
cascade reaction could provide a quick synthesis to this system.  However, there are 
some key differences that need to be addressed.  These natural products contain a 
tertiary amine, which is not present in our products.  There are possible routes to 
introduce this functionality.  For example, replacement of the methyl ketone of the 
Michael acceptor with an imine should lead to similar products.  However, all attempts at 
this proposed reaction were unsuccessful.  We then envisioned that this compound 
could be reached by a Ritter reaction with the tertiary alcohol of the final compound.  
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We initially ventured to synthesize Crescentin IV using this methodology.  Synthetically, 
it bears a cyclopentane core that can be easily accessed through this methodology.  
Two major obstacles were present: 1) conversion of the ketone group to a 
hydroxymethyl substituent, and 2) conversion of the ester moiety to a hydroxyl group.  
Manipulation of the ketone would be straightforward, employing a methylenation of the 
carbonyl (either by Wittig or with the Petasis reagent) followed by a diastereoselective 
hydroboration (followed by oxidation).  Replacement of the ester group proved 
challenging.  Initial ideas employed the formation of an acyl-peroxide.  These are known 
to be unstable, and after decarboxylation, will leave an acyloxy group.  After critical 
thinking, we determined both of these issues can be resolved by the use of excess 
Petasis reagent.  Not only would this olefinate the ketone moiety, but also the carbonyl 
of the ester.  Mild hydrolysis would reveal the exocyclic methyl ketone.  Hydroboration of 
the newly formed alkene would install the hydroxymethyl group, and a simple Baeyer-
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Initial work lead to a cascade product with a protected propanol group, similar to the 
natural product (21r, Scheme 2.16).  Treatment of this product to the Petasis reagent 
was successful, forming the enol ether in 20% yield.  Hydrolysis led to the methyl ketone 
in a 57% yield (not shown).  Optimization shows that protection of the tertiary alcohol 
improves the reaction, and addition of silica gel to the reaction mixture allows for the in 
situ hydrolysis of the enol ether to form 29 in up to 66% yield.  Initial studies show that 
thexyl-borane is capable of the hydroboration of the alkene to form alcohol 30.  At the 
time, the determination of diastereoselectivity proved difficult.   It was also at this time 
that we decided to discontinue this synthesis.  The concurrent determination of the 
crystal structure revealed that the orientation of the tertiary alcohol formed was 
incongruent with Crescentin IV, and the synthesis of this compound was abandoned. 
 
 In conclusion, a cascade reaction was developed for the synthesis of complex 
cyclopentanones in high stereoselectivity.  This reaction compliments our previously 
established work.  In addition, our work revealed a unique synergistic cooperation 
between the amine catalyst and the NHC catalyst.  We believe that elaboration of these 
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CHAPTER 3 
ASYMMETRIC AMINOMETHYLATION OF ENALS BY NHC CATALYSIS 
 
 
3.1 Homoenolate Background 
 Formation of the Breslow Intermediate is key for observing Umpolung reactivity.  
This intermediate is formed via the addition of an NHC to an aldehyde.  With enals, 
however, complications arise as the acyl anion is now allylic.  Consequently, 
nucleophilicity can be observed β to the aldehyde (Scheme 3.1).  As such, this is 
termed as ‘homoenolate’ reactivity.71   
Scheme 3.1  
 Bode72 and Glorius73 concurrently reported an example of this with the formation 
of a γ-lactone that arises from cinnamaldehyde and aryl aldehydes (Scheme 3.2).  In 
this reaction, the enal/NHC adduct undergoes nucleophilic addition with either an 
aldehyde or ketone at the homoenolate position to form adduct III.  Proton transfers lead 
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Scheme 3.2  
 This technology has led to efficient, practical syntheses of a variety of different 
carbocycles and heterocycles.71 Recently, there has been a push to develop reactions 
that form acyclic products.  Nair and coworkers reported initial work coupling enals with 
chalcones to form straight-chain products (though this was observed as a side 
product).74  This was followed by further work employing nitro-olefins as substrates.75  
This was expanded with reports of an asymmetric variant from the Liu group76 and a 
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Scheme 3.3  
 Our initial proposal intended for the catalytic formation of an acyl azolium 
intermediate by oxidative methods, leading to an activated olefin susceptible to 
cycloaddition chemistry.  This strategy has been utilized by the Lupton lab to form cyclic 
systems.78  We envisioned that a [3+2] cycloaddition between enal 3 and iminium 
precursor 18 would form pyrrolidine 20.  Unfortunately, only fa side-product was 
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compound 21, which seems to arise from the homoenolate addition of the 
cinnamaldehyde and the iminium (Scheme 3.4).   
 
Scheme 3.4  
 This was a fortuitous discovery, as this presents a simple strategy to construct 
substituted γ-aminobutyrates.  The backbone resembles GABA (22, Fig 3.1), an 
essential mammalian neurotransmitter.  Derivatives of this compound often display 
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3.2 Reaction Optimization 
 Attracted by the opportunity to quickly access GABA derivatives, we sought to 
optimize the reaction.  A screen of our achiral catalysts revealed that electron-deficient 
catalysts give satisfactory results, whereas the electron rich N-phenyl (23) and mesityl  
(24) catalysts yielded no desired product (Table 3.1).   
Table 3.1  
 
 While initial results were positive, the impact of the base was explored  (Table 
3.2).  A full equivalent of base was found to be optimal.  Carboxylate  
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bases were also effective, with acetates and pivalates providing good yields.   
However, certain counterions (Li or Cs) lead to side-reactions and lower than  
expected yield.  Stronger bases, such as DBU and K2CO3, provided no product. 
 Solvent choice has a significant impact on the availability of the iminium 
precursor.  NMR experiments indicate that in tAmOH, a diamino-acetal is formed, which 
is a less reactive iminium precursor compared to the N,O-acetal (Fig 3.2).79  In contrast, 
in ethanol or methanol, the parent N,O-acetal remains intact.  Exchange of the alkoxy 
groups is also observed between the parent acetals and solvent.   The use of organic 
cosolvents, such as THF, toluene, or DCM, promoted formation of the hydrocinnamates.  
This is the product of simple protonation of the homoenolate intermediate, which is often 
termed ‘proteo-redox.’80 
 
Figure 3.2  
 With methanol and ethanol as excellent solvents at preserving the acetal, several 
catalysts were rescreened to gauge further improvement in yield.  The use of the 
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observations made by my colleague Nick White who proposed increasing the steric bulk 
in the catalyst can inhibit acyl-anion reactivity and promote homoenolate chemistry. 
Table 3.3  
 
 With suitable conditions, the scope of the racemic reaction was explored (Table 
3.4).  Electron-deficient enals are tolerated in this reaction (36b and 36c) as well as 
electron-rich enals (36d, f-g).   
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Heterocycles show mixed results, with furan demonstrating success (36e) whereas 2-
pyridyl leads to no desired product (not shown).   Variation of the amine is tolerated, 
allowing for different deprotection strategies (36h). 
 
3.3 Asymmetric Homoenolate/Mannich Reaction 
 We sought to render this reaction asymmetric.  When t-amyl alcohol was used, 
none of our typical NHC catalysts induced asymmetry (Fig 3.4a).  The initial hypothesis 
was that the increased steric bulk of the chiral catalysts impeded catalyst turnover by 
methanol and interrupted the catalytic cycle.  
 
Figure 3.4  
 One solution to this issue is to decrease the size of the catalyst.  We decided to 
test catalyst 38 developed by my colleague, Daniel DiRocco, for the asymmetric Stetter 
reaction.81  This bears a single, remote fluorine-containing stereocenter, effectively 
making this the same size as an achiral catalyst.  This catalyst provides product in 60% 
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Scheme 3.4  
 This enantioselectivity was much higher than expected due to the small steric 
impact of the fluoride that is distant from the active site of the catalyst.  We then sought 
to improve the stereoselectivity of this reaction.  Using cosolvents such as THF or 
CHCl3 provided no product, only hydrocinnamate products (Table 3.5).  Toluene as co-
solvent improved enantioselectivity slightly to 55% ee.  Methanol effectively erases any 
enantioselectivity.  Reduction in reaction temperature also lowers yield and 
enantioselectivity. 
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 Regarding catalyst design, the introduction of the N-tribromophenyl group (39) 
led to a decrease in selectivity (Scheme 3.5).  While interesting, there were no 
promising trends with this catalyst, and alternative strategies were explored. 
 
Scheme 3.5  
 Maintaining the hypothesis the catalyst turnover was problematic with the larger 
chiral catalyst, a change of solvent was explored.  An HTE (High Throughput 
Experimentation) screen with several aminoindanol based catalysts was tested against 
three different alcohol solvents and eight different bases.  To our delight, these catalysts 
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Figure 3.3 
Scaling up the reaction using the catalyst 33 in methanol reveals formation of product in 
54% yield and 38% ee (Scheme 3.6). 
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Curiously, this system was unsuitable for other catalysts.  However, using a mixture of t-
amyl alcohol and methanol allows for bulky, electron-deficient catalysts to be utilized 
(Scheme 3.7).  Unfortunately, results remain mediocre (Table 3.6). 
   
Scheme 3.7  
Table 3.6  
 
 NHC catalysts bearing a bicyclic backbone are also effective in this reaction 
(Table 3.7).  Benzyl substituted catalyst 46 formed the desired product in low yields.  
The cyclohexyl substituted catalyst 47 showed improved reactivity, with similar results 
with EtOH as the solvent.  However, not all catalyst scaffolds failed to yield any desired 
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favors homoenolate reactivity in our work with nitroolefins,77 does not lead to product 
formation in this reaction.  
Table 3.7  
 
 The nature of the iminium precursor was also explored (Table 3.8).  Activated 
aminals proved to be highly reactive and unstable, while the substituted iminium 53 was 
unreactive as a substrate. 
Table 3.8  
 
 Even though some progress has been made, a general solution for rendering this 
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reveal no promising trends, so the best direction seems to be in the design of new 
catalysts.  Chapter 4 will provide detail in these efforts.  However, at this time a suitable 
catalyst has yet to be discovered. 
 
3.4 NHC Catalyzed Aza-Morita-Baylis-Hilman 
 A persistent challenge encountered in this chemistry is reaction selectivity.  
During the course of these studies, products formed from side reactions were isolated in 
varying amounts.  The hydrocinnamate product (54), derived from the protonation of the 
homoenolate equivalent, is one side-product that was expected (Figure 3.5). 
 
Figure 3.5  
In addition, an aza-benzoin product (55) is occasionally formed in the course of this 
reaction.  This is most often seen with the use of catalyst 37.  This is not a surprising 
result, as similar products were reported by López-Calahorra.82   
 
 An unexpected result was the formation of the aza-Morita-Baylis-Hilman adduct 
56.  While there has been extensive work with this reaction, reports using NHC catalysis 
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between cyclic enones and tosyl-imines (Scheme 3.7a).83  In a related reaction, Scheidt 
and coworkers reported an NHC catalyzed Rauhut-Currier reaction with enals and 
bis(sulfonyl)alkenes (Scheme 3.7b).84  With few examples reported, we decided to 
explore this reaction further. 
 
Scheme 3.7  
 With the help of a talented undergraduate student, Adam Golos, the reaction was 
optimized.  The initial hit for the reaction was with chiral catalyst 64 with an N-phenyl 
group (Table 3.9).  While the yields were adequate, this catalyst demonstrated 
increased selectivity for this product.  With trifluoroethanol as solvent, the yield of the 
reaction is drastically improved.  However, we found it superfluous to use a chiral NHC 
catalyst to form achiral products.  Various achiral catalysts were screened, and catalyst 
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Table 3.9  
 
 With suitable conditions at hand, Golos worked on elucidating the scope of the 
reaction (Table 3.10).  Electron-deficient enals make excellent substrates, with cyano-
cinnamaldehyde being the exception (56b-d).   
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Electron-rich enals are not well tolerated, and a furyl group shuts down reactivity(56e-f).  
In terms of substitution, o-bromo-cinnamaldehyde (56h) performs better than p-
bromocinnamaldehyde (56g), while the m-substitution is not well tolerated (56i).  A 
butenoate substrate  provides the expected product 56j, albeit in low yields.  This is 
notable as this enal is not a suitable substrate in the homoenolate chemistry.   Alkyl-
substituted enals are not converted to product. 
 
 Substitution of the amine with various protecting groups is tolerated (Table 3.11).  
The dibenzylamine and allyl benzylamine lead to product formation in high conversion 
(56l-m).  The use of a morpholine based acetal is also effective (56o), allowing for the 
incorporation of heterocycles. 
Table 3.11  
 
 In conclusion, our work has revealed new synthetic access to γ-aminobutyrates 
through a homoenolate/Mannich reaction.  This route provides access to a biologically 
relevant group of compounds.  As of yet, we have not discovered conditions to form 
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certainly be achieved.  In addition, we have revealed a rare case of an aza-Morita-
Baylis-Hilman reaction using NHC catalysis. 
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CHAPTER 4 






4.1 Significance of Catalyst Design 
 In our group’s work in Rhodium catalysis, we see strong impact from the 
selection of ligand, and catalyst design has emerged as a strong tradition.  For example, 
in the Rh-catalyzed [2+2+2] cycloaddition, the use of the perfluorinated phosphoramidite 
ligand 2 shows enhanced selectivity (Scheme 4.1a).85  In the Rh(III)-catalyzed formation 
of pyridones from acrylamides, there is a substantial enhancement of regioselectivity 
with a bis(t-butyl) substituted Cp ligand 4 is used instead of pentamethyl Cp 3 (Scheme 
4.1b).86  The same is observed in recent work describing the Rh-catalyzed 
cyclopropanation of acrylates (Scheme 4.1c).87  As such, catalyst design is considered 
critical for reaction success. 
 Design and modification of N-heterocyclic carbene catalysts has also led to 
significant improvements in reaction performance.  One example is work accomplished 
by my colleague Daniel DiRocco in his work with the asymmetric intermolecular Stetter 
reaction with nitroalkenes (Scheme 4.2).  He designed NHC catalyst 7 that bears a 
single fluoride on the backbone, distant from the active site.88  The single modification 
leads to significant improvements in enantioselectivity. Lessons learned from this 
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achievement were critical for the success of future asymmetric intermolecular Stetter 




In the development of the asymmetric homoenolate addition of enals with nitroalkenes, 
Nicholas White explored catalyst modification to improve selectivity (Scheme 4.3).90  His 
work revealed that pyroglutamate-derived catalysts were the most promising.  While the 
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enhance selectivity.  Indeed, the dibutyl-catalyst 9 was key to the success of this 
reaction. 
Scheme 4.3 
 In NHC catalysis, our group employs two classes of catalysts: amino-acid based 
and aminoindanol based (Figure 4.1).91  The NHC catalysts derived from amino-acids 
have proven to be a reliable scaffold due to the variety of chiral amino-acids, both 
natural and synthetic, that can serve as starting material for catalyst synthesis.  
Inherently, a diversity of catalysts can be rapidly constructed.  
 
Figure 4.1  
 The aminoindanol scaffold, for the time being, has proven difficult to modify.  The 
enantioenriched aminoindanol (Fig 4.2) is a key structural compound of the HIV drug 
indinavir92 (trade name: Crixivan).  With large amounts of this compound available, the 
enantioenriched aminoindanol can also be found in other catalysts.  These include in 
PHOX ligands,93 BOX ligands,94 as well as chiral thiourea catalysts.95  While popular, 
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Figure 4.2 
4.2 Modification of Aminoindanol Scaffold 
 One example is work reported by the Katsumara group.96  Their work is 
concerned with the development of an asymmetric 6π cyclization as a method to form 
enantioenriched piperidines (12, Scheme 4.4).  Crucial to this reaction was the use of 
the chiral aminoindanol 10 as an auxiliary.  Initial work with auxiliary 10a produced 
compounds in a 3:1 dr.  As a route to improve this, they explored installing alkyl groups 
to the C-7 site of the aminoindanol.  This dramatically improves diastereoselectivity to 
an impressive 40:1 dr with 10b.  It should be noted, however, that the synthesis of these 
modified amino-indanols can be lengthy, involving between 9-11 steps.  This provides a 
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 Work by Bode and coworkers provide another great example.  In the kinetic 
resolution of chiral secondary amines, they employ chiral hydroxamic acid co-catalyst 
14 derived from the aminoindanol (Scheme 4.5).97  An improvement in S-factor is 
observed with a catalyst bearing a bromide at C-6 (14b).  Dibromination, on the other 
hand leads to no improvement in selectivity.  In addition, these aminoindanol variants 
are fairly simple to produce: electrophilic bromination under acidic conditions yields the 
6-substituted bromide selectively from the parent lactam. 
Scheme 4.5 
 Besides electrophilic bromination, the aminoindanol scaffold is susceptible to 
nitration at the 6-position as well.  This was exploited by Takasu and Yamada for the 
synthesis of nitrated aminoindanol derivatives 16 (Scheme 4.6).98  The material was 
taken on to construct a triazolium salt used for the kinetic resolution of meso-diols 15.  
The nitrated-aminoindanol is not completely unprecedented, as a group from Eli Lilly 
used this scaffold for the synthesis of an M1 agonist.99  However, they use a parent 
nitro-indanone as starting material in contrast to the late stage installation demonstrated 
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 In the course of research at CSU, we were curious about methods for late-stage 
modification of our triazolium salts.  This was inspired by work of Waser and Bode 
(Scheme 4.7).  Waser reported the late stage modification of a triazolium salt 17 by 
careful reduction of a tethered azide.100  The primary amine formed is then captured by 
a thioisocyanate to form a pendant thiourea side chain.  In a similar fashion, Bode used 
a similar starting strategy to arrive at triazolium 19 bearing a primary amine,101 which is 
then condensed with various 1,4-diketones to quickly access a variety of catalysts with 
pyrrole side chains (20). 
Scheme 4.7 
 Concurrently, we explored ways for the late stage modification of catalysts as 
well.  However, basic conditions lead to the deprotonation of the triazolium and can 
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catalysts met with failure (Scheme 4.8).  A method to ‘protect’ the triazolium from basic 
conditions would allow for easy modification, and so we sought methods that can serve 
as a way to protect the catalyst. 
 
Scheme 4.8 
 One such idea came during the discovery of the ‘aza-Breslow’ intermediate.  
DiRocco encountered this adduct in his work in the aza-benzoin reaction.102  Exposure 
of a triazolilylidene with an iminium leads to the formation of compound 24 (Scheme 
4.9).  Furthermore, this formation is reversible, and the free NHC 25 can be liberated by 
acidic conditions.  With easy formation and recovery, this showed promise as a way to 
protect the triazolium.  Unfortunately, isolation of stable aza-Breslow intermediate is 
limited to a few specific systems.   
Scheme 4.9 
 We imagined that reducing the triazolium to the triazoline would access 
intermediates that would tolerate basic conditions.  Reduction by Pd-catalyzed 
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explored.  Sodium borohydride (NaBH4) is an effective reagent, but conditions proved 
harsh and yields are low.  By running the reaction at 0 °C in a 10:1 ratio of DCM/EtOH 
(or DCM/H2O), the product can be isolated cleanly (see Table 4.1).  Dependent on the 
purity of the starting material, the reduction proceeds cleanly and no further purification 
is needed.  For milder conditions, sodium triacetoxyborohydride (NaBH(OAc)3) can be 
used as well, but this is limited to electron-deficient catalysts (i.e.: catalysts bearing an 
N-pentafluorophenyl group).  Plenio and coworkers employed this strategy in their 
modification of imidazolinium-based catalysts.103   
 
4.3 Oxidation by Trityl Salts to Form Triazoliums 
 With a method to convert triazoliums to triazolines, we then explored conditions 
for the reverse reaction.  Bildstein and coworkers described the synthesis of 
benzimidazolines bearing an N-ferrocenyl group and an N-Methyl group.104   This is then 
oxidized to the benzimidazolium salt 27 by exposure to triphenylcarbenium (aka trityl) 
tetrafluoroborate (Scheme 4.10a).  We were curious if this strategy would work to form 
triazoliums.  To our delight, exposure of the triazoline 28 to trityl BF4 at room 
temperature in DCM led to clean conversion to the desired triazolium 29 (Scheme 
4.10b).  A method was then sought to separate the triphenylmethane side-product from 
the triazolium.  This can be accomplished by addition of diethyl ether to the reaction.  
The triazolium salt precipates as a powdery solid, and filtration separates the product 
from any waste material.  In contrast to our traditional catalyst synthesis, where 
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formation of a workable solid can sometimes be elusive, this approach reliably provides 
the catalyst as a free flowing solid. 
 
Scheme 4.10 
 We then screened this method with various triazolines.  This reaction works well 
with electron-rich, electron-deficient, and bulky substrates (Table 4.1).  Additionally, the 
method can be used to introduce new counterions, such as hexafluorophosphate (29b) 
and hexachloroantimonate (29c).  Chiral substrates (30 and 31) also are competent in 
this reaction. 
 A direct synthesis of triazolines, side-stepping the reduction of a triazolium, would 
be a welcome advantage for this method.105  Similar to what Bildstein reported, we 
imagine that formation of a hydrazide followed by cyclization with formaldehyde would 
yield the triazoline.106  Unfortunately, attempts with cyclization were unsuccessful and 
only starting material was isolated (Scheme 4.11).  Under more forcing conditions, the 
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Other C1 sources were explored, including diiodomethane,107 dibromomethane, 
dimethoxymethane, and the Glorius reagent (chloromethyl pivalate),108 but no desired 
product was formed.    It was at this time that a visiting graduate student, Milind Jadhav 
of the University of Camerino, continued in the search for conditions to synthesize a 
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 One issue that manifested itself during this work was the lability of triazolines.  
Under acidic conditions, these products decompose.  The electronics of the N-aryl 
group seem to have the biggest impact in this property.  Phenyl and methoxy-phenyl 
substituted triazolines decompose upon exposure to silica gel, and the methoxy-phenyl 
variant can degrade at room temperature after several days.  Electron-deficient analogs 
tend to show increased stability, and can tolerate column chromatography with silica 
gel.  With this in mind, purification of triazolines is usually accomplished with basic 
alumina as the solid phase.  Similar observations were described by Plenio and 
coworkers in their work with imdazoliniums.  In their report, symmetrical imidazolines 
are accessed by condensation with formaldehyde, but unsymmetrical analogs proved 
difficult.  They thus formed the imidazolium salt and reduced to the desired compound, 
which is the route we selected. 
 
4.4 Cross-Coupling as Strategy for Late-Stage Modfication 
 Our initial strategy involved alkylation of an NHC catalyst.  A triazoline with a free 
hydroxyl group can be accessed from pyroglutamic acid.  Our aim was to attach an 
additive at this position.  Previous work has demonstrated some key additives that 
improve various NHC catalyzed reactions, specifically carboxylic acids and 
catechol.109,110  My colleague, Phil Goldblatt, explored the syntheses of these 
compounds (Scheme 4.12).  However, this chapter will focus on the manipulation of the 
aminoindanol scaffold.   







 The brominated lactam, as reported by Bode, could provide opportunity for 
downstream modifcation.  Bromination of the amide precursor formed the precursor 36 
(Scheme 4.13).  The material is carried forward through traditional catalyst synthesis,113 
then reduced with NaBH4 and purified by column chromatography (Scheme 4.13).  This 
provides product 37 as a clean solid that is easy to work with.  
 
Scheme 4.13 
 We decided the aryl bromide would serve as an excellent substrate for a Suzuki-
Miyaura cross-coupling.111  This would be useful method for the introduction of aryl 
groups to this scaffold.  To fully appreciate this, it is worth examining an X-ray crystal 
structure obtained of the aminoindanol-based catalyst (Fig 4.3).112  The aryl group of the 
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effective in imparting enantioselectivity in acyl-anion chemistry, as seen in successful 
cases of asymmetric benzoin and Stetter reactions (see Chapter 1).  However, with the 
emergence of homoenolate chemistry with NHC catalysis, this conformation might have 
little effect in setting the more distant stereocenter.  Installing large substituents on the 
aminoindanol could be a remedy. 
 
Figure 4.3 
 To determine optimal conditions for the Suzuki coupling, High-Throughput 
Experimentation (HTE) was employed.  HPLC results from the HTE experiment show 
two promising set of conditions (Fig 4.4).  While sodium hydroxide (NaOH) proved to be 
a false positive, the potassium phosphate (K3PO4) hit gave promising results.  When 
this reaction was conducted at the bench, the desired compound was isolated in 63% 


















 With optimal conditions discovered, we set out to synthesize a variety of 
elaborated triazolines (Table 4.2).  Electron-rich aryl boronic acids are superb as 
substrates, whereas electron-deficient partners give product in diminished yields.  Even 
some bulky aromatic species are tolerated.  There is a limit, however, as very bulky and 





























 With elaborated triazolines at hand, we tested if trityl salt mediated oxidation will 
work on these substrates.  To our delight, this reoxidation does work to provide the 
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Table 4.3 
 
 For a shorter synthesis, cross-coupling can be performed on the bromo-lactam 
precursor 36 followed by traditional catalyst synthesis to form 41 (Scheme 4.14).113 
 
Scheme 4.14 
 We were curious if cross-coupling can occur on the N-Aryl group as well.  The 
use of p-iodophenylhydrazine as starting material introduces a C-I bond that can be 
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way to introduce highly electron-releasing substituents onto the N-aryl group of the 
triazolium catalysts (Table 4.4).  NHC catalysts that contain highly electron-donating 
groups on the arene often possess unique capabilities.114  However, the parent 
hydrazines are highly unstable, so an alternative synthetic strategy would prove useful.  
Unfortunately, no desired products were formed:  the triazoline substrate 43 is unstable, 
and decomposes under attempted literature conditions.115 
Table 4.4 
 
 A future direction for this project would be the development of a simple triazoline 
precursor.  If simple N-H variant 45 can be accessed, this can serve as a substrate for 
diversification by simple alkylation or arylation (Scheme 4.15).  Oxidation to the 
triazolium would provide a convenient route to many different NHC catalysts.  This 
strategy would avoid two major pitfalls in catalyst synthesis: 1) usage of unstable aryl 
hydrazines, and 2) difficult cyclization to form the triazole core.  However, a practical 
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Scheme 4.15 
 In summary, a useful strategy for the diversification of aminoindanol-based NHC 
catalysts has been described.  This will serve in the exploration of new catalysts in the 



















1	  Wöhler, F.; Liebig, J. Annalen der Pharmacie 1832, 249-282. 
2 Ugai, T.; Tanaka, R.; Dokawa, T. J. Pharm. Soc. Jpn. 1943, 63, 296-300. 
3 Breslow, R. J. Am. Chem. Soc. 1958, 80, 3719-3726. 
4 Lapworth, A. J. Chem. Soc. 1903, 83, 995-1005. 
5 Seebach, D. Angew. Chem. Int. Ed. 1979, 18, 239-258. 
6 a) Stetter, H.; Schrekenberg, M. Angew. Chem. Int. Ed. Engl. 1973, 12, 81. b) Stetter, 
H. Angew. Chem. Int. Ed. Engl. 1976, 15, 639-647. 
7 Enders, D.; Han, J.; Henseler, A. Chem. Commun. 2008, 34, 3989-3991. 
8 a) see ref 7. b) Bugaut, X.; Liu, F.; Glorius, F. J. Am. Chem. Soc. 2011, 133, 8130-
8133. 
9 a) Chiang, P.-C.; Rommel, M.; Bode, J. W. J. Am. Chem. Soc. 2009, 131, 8714-8718. 
b) Wanner, B.; Mahatthananchai, J.; Bode, J. W. Org. Lett. 2011, 13, 5378-5381. c) 
Binanzer, M.; Hsieh, S.-Y.; Bode, J. W. J. Am. Chem. Soc. 2011, 133, 19698-19701. d) 
Hsieh, S.-Y.; Binanzer, M.; Kreituss, I.; Bode, J. W. Chem. Commun. 2012, 48, 8892-
8894. 
10 Stetter, H.; Kuhlmann, H. Org. React. 1991, 40, 407-496. 
11 Kerr, M. S.; Read de Alaniz, J.; Rovis, T. J. Am. Chem. Soc. 2002, 124, 10298-
10299. 
12 Ciganek, E. Synthesis 1995, 1311 
13 Vacca, J. P.; Dorsery, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; 
Zugay, J.; Quintero, J. C.; Blanhy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; 
Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Vastag, K.; 
Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. Proc. Natl. Acad. Sci. U.S.A. 1994, 
91, 4096. 
14 Kerr, M. S.; Rovis, T. J. Am. Chem. Soc. 2004, 126, 8876-8877. 
15 Read de Alaniz, J.; Rovis, T. J. Am. Chem. Soc. 2005, 127, 6284-6289. 
16 Liu, Q.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 2552-2553. 
17 Enders, D.; Han, J.; Henseler, A. Chem. Commun. 2008, 3989-3991. 
18 see ref. 10 
19 Liu, Q.; Perreault, S.; Rovis, T. J. Am. Chem. Soc. 2008, 130, 14066-14067. 
20 Liu, Q.; Rovis, T. Org. Lett. 2009, 11, 2856-2859. 
21 DiRocco, D. A.; Oberg, K. M.; Dalton, D. M.; Rovis, T. J. Am. Chem. Soc. 2009, 131, 
10872-10874. 
22 Um, J. M.; DiRocco, D. A.; Noey, E. L.; Rovis, T.; Houk, K. N. J. Am. Chem. Soc. 
2011, 133, 11249-11254. 
23 DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2011, 133, 10402-10405. 
24 DiRocco, D. A.; Noey, E. L.; Houk, K. N.; Rovis, T. Angew. Chem. Int. Ed. 2012, 51, 
2391-2394. 
25 Sánchez-Larios, E.; Thai, K.; Bilodeau, F.; Gravel, M. Org. Lett. 2011, 13, 4942-4945. 
26 Piel, I.; Steinmetz, M.; Hirano, K.; Fröhlich, R.; Grimme, S.; Glorius, F. Angew. Chem. 
Int. Ed. 2011, 50, 4983-4987. 
	   77	  
27 Biju, A. T.; Wurz, N. E.; Glorius, F. J. Am. Chem. Soc. 2010, 132, 5970-5971. 
28 Bugaut, X.; Liu, F.; Glorius, F. J. Am. Chem. Soc. 2011, 133, 8130-8133. 
29 Schedler, M.; Wang, D.-S.; Glorius, F. Angew. Chem. Int. Ed. 2013, 52, 2585-2589. 
30 Enders, D.; Kallfass, U. Angew. Chem. Int. Ed. Engl. 2002, 41, 1743-1745. 
31 Langdon, S. M.; Wilde, M. M. D.; Thai, K.; Gravel, M. J. Am. Chem. Soc. 2014, 136, 
7539-7542. 
32 Takikawa, H.; Hachisu, Y.; Bode, J. W.; Suzuki, K. Angew. Chem. Int. Ed. 2006, 45, 
3492-3494. 
33 Takikawa, H.; Suzuki, K. Org. Lett. 2007, 9, 2713-2716. 
34 Castells, J.; López-Calahorra, F.; Bassedas, M.; Urrios, P. Synthesis 1988, 314-315. 
35 Murry, J. A.; Frantz, D. E.; Soheili, A.; Tillyer, R.; Grabowski, E. J. J.; Reider, P. J. J. 
Am. Chem. Soc. 2001, 123, 9696-9697. 
36 DiRocco, D. A.; Rovis, T. Angew. Chem. Int. Ed. 2012, 51, 5904-5906. 
37 DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2012, 134, 8094-8097. 
38 DiRocco, D. A.; Oberg, K. M.; Rovis, T. J. Am. Chem. Soc. 2012, 134, 6143-6145. 
39 a) Reynolds, N. T.; Read de Alaniz, J.; Rovis, T. J. Am. Chem. Soc. 2004, 126, 9518-
9519. b) Chow, K. Y.-K.; Bode, J. W. J. Am. Chem. Soc. 2004, 126, 8126-8127. c) 
Sohn, S. S.; Rosen, E. L.; Bode, J. W. J. Am. Chem. Soc. 2004, 126, 14370-14371. d) 
Burstein, C.; Glorius, F. Angew. Chem. Int. Ed. 2004, 43, 6205-6208. 
40 a)Wallach, O. Ber. Dtsch. Chem. Ges. 1873, 6 b) Kötz, A. J. Prakt. Chem. 1913, 88, 
531-532. 
41 a) Reynolds, N. T.; Rovis, T. J. Am. Chem. Soc. 2005, 127, 16406-16407. b) also see 
39a 
42 Wheeler, P.; Vora, H. U.; Rovis, T. Chem. Sci. 2013, 4, 1674-1679. 
43 Zhao, X.; DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2011, 133, 12466-12469. 
44Raup, D. E. A.; Cardinal-David, B.; Holte, D.; Scheidt, K. A. Nat. Chem. 2010, 2, 766- 
45Kaeobamrung, J.; Mahatthananchai, J.; Zheng, P.; Bode, J. W. J. Am. Chem. Soc. 
2010, 132, 8810-8812. 
46 Zhao, X.; Ruhl, K. E.; Rovis, T. Angew. Chem. Int. Ed. 2012, 51, 12330-12333. 
47 White, N. A.; DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2013, 135, 8504-8507. 
48 Kerr, M. S.; Rovis, T. J. Am. Chem. Soc. 2004, 126, 8876-8877. 
49 Massey, R. S.; Collett, C. J.; Lindsay, A. G.; Smith, A. D.; O’Donoghue, A. C. J. Am. 
Chem. Soc. 2012, 134, 20421-20432. 
50 Collett, C. J.; Massey, R. S.; Maguire, O. R.; Batsanov, A. S.; O’Donoghue, A. C.; 
Smith, A. D. Chem. Sci. 2013, 4, 1514-1522. 
51 For some recent reviews, see: a) Grondal, C.; Jeanty, M.; Enders, D. Nat. Chem. 
2010, 2, 167-178. b) Pellissier, H. Tetrahedron 2013, 69, 7171-7210. c) Pellissier, H. 
Adv. Synth. Catal. 2012, 354, 237-294. d) Albrecth, L.; Jiang, H.; Jørgensen, K. A. 
Angew. Chem. Int. Ed. 2011, 50, 8492-8509. e) Patil, N. T.; Shinde, V. S.; Gajula, B. 
Org. Biomol. Chem. 2012, 10, 211-224. d) Allen, A. E.; MacMillan, D. W. C. Chem. Sci. 
2012, 3, 633-658. 
52 Some excellent examples include: a) Huang, Y.; Walji, A. M.; Larsen, C. H.; 
MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 15051-15053. b) Zhou, J.; List, B. J. 
Am. Chem. Soc. 2007, 129, 7498-7499. c) Wang, Y.; Han, R.-G.; Zhou, Y.-L.; Yang, S.; 
	   78	  
Xu, P.-F.; Dixon, D. J. Angew. Chem. Int. Ed. 2009, 48, 9834-9838. d) Belot, S.; Vogt, 
K. A.; Besnard, C.; Krause, N.; Alexakis, A. Angew. Chem. Int. Ed. 2009, 48, 8923-
8926. e) Simmons, B.; Walji, A. M.; MacMillan, D. W. C. Angew. Chem. Int. Ed. 2009, 
48, 4349-4359. f) Quintard, A.; Alexakis, A.; Mazet, C. Angew. Chem. Int. Ed. 2011, 50, 
2354-2358. 
53 Nemoto, T.; Fukuda, T.; Hamada, Y. Tetrahedron Lett. 2006, 47, 4365-4368. 
54Lebeuf, R.; Hirano, K.; Glorius, F. Org. Lett. 2008, 10, 4243-4246. 
55 Biju, A. T.; Wurz, N. E.; Glorius, F. J. Am. Chem. Soc. 2010, 132, 5970-5971. 
56Padmanaban, M.; Biju, A. T.; Glorius, F. Org. Lett. 2011, 13, 5624-5627. 
57 Lathrop, S. P.; Rovis, T. J. Am. Chem. Soc. 2009, 131, 13628-13630.  For related 
work, see: Jacobsen, C. B.; Jensen, K. L.; Udmark, J.; Jørgensen, K. A. Org. Lett. 2011, 
13, 4790-4793. 
58 a) Liu, G.; Wilkerson, P. D.; Toth, C. A.; Xu, H. Org. Lett. 2012, 14, 858-861. b) Li, J.-
L.; Sahoo, B.; Daniliuc, C.-G.; Glorius, F. Angew. Chem. Int. Ed. 2014, Early View, DOI: 
10.1002/anie.201405178. c) Fu, Z.; Sun, H.; Chen, S.; Tiwari, B.; Li, G.; Chi, Y. R. 
Chem. Commun. 2013, 49, 261-263.  
59 For example, see: Jiang, H.; Elsner, P.; Jensen, K. L.; Falcicchio, A.; Marcos, V.; 
Jørgensen, K. A. Angew. Chem. Int. Ed. 2009, 48, 6844-6848. 
60 Filloux, C. M.; Lathrop, S. P.; Rovis, T. Proc. Natl. Acad. Sci. USA 2010, 107, 20666-
20671. 
61 a) DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2011, 133, 10402-10405. b) Peelen, 
T. J.; Chi, Y.; Gellman, S. H. J. Am. Chem. Soc. 2005, 127, 11598-11599. c) Fang, X.; 
Chen, X.; Lv, H.; Chi, Y. R. Angew. Chem. Int. Ed. 2011, 50, 11782-11785. 
62 Wang, J.; Ma, A.; Ma, D. Org. Lett. 2008, 10, 5425-5428. 
63 see ref 58, 59, and also: a) Campbell, M. J.; Johnson, J. S. J. Am. Chem. Soc. 2009, 
131, 10370-10371. b) Chen, K.; Baran, P. S. Nature 2009, 459, 824-828. 
64 Ozboya, K. E.; Rovis, T. Chem. Sci. 2011, 2, 1835-1838. 
65 Stetter product formed:  
66 Moore, J. L.; Silvestri, A. P.; Read de Alaniz, J.; DiRocco, D. A.; Rovis, T. Org. Lett. 
2011, 13, 1742-1745. 
67 a) Krautwald, S.; Sarlah, D.; Schafroth, M. A.; Carreira, E. M. Science 2013, 340, 
1065-1068. b )Krautwald, S.; Schafroth, M. A.; Sarlah, D.; Carreira, E. M. J. Am. Chem. 
Soc. 2014, 136, 3020-3023. 
68 Su, S.; Seiple, I. B.; Young, I. S.; Baran, P. S. J. Am. Chem. Soc. 2008, 130, 16490-
16491. 
69 a) Seiple, I. B.; Su, S.; Young, I. S.; Lewis, C. A.; Yamaguchi, J.; Baran, P. S. Angew. 
Chem. Int. Ed. 2010, 49, 1095-1098. b) Seiple, I. B.; Su, S.; Young, I. S.; Nakamura, A.; 
Yamaguchi, J.; Jørgensen, L.; Rodriguez, R. A.; O’Malley, D. P.; Gaich, T.; Köck, M.; 
Baran, P. S. J. Am. Chem. Soc. 2011, 133, 14710-14726. 
70 Kaneko, T.; Ohtani, K.; Kasai, R.; Yamasaki, K.; Duc, N. M. Phytochemistry 1997, 46, 
907-910. 
71 Nair, V.; Menon, R. S.; Biju, A. T.; Sinu, C. R.; Paul, R. R.; Jose, A.; Sreekumar, V. 







	   79	  
72 Sohn, S. S.; Rosen, E. L.; Bode, J. W. J. Am. Chem. Soc. 2004, 126, 14370-14371. 
73 Burstein, C.; Glorius, F. Angew. Chem. Int. Ed. 2004, 43, 6205-6208. 
74 Nair, V.; Babu, B. P.; Vellalath, S.; Varghese, V.; Raveendran, A. E.; Suresh, E. Org. 
Lett. 2009, 11, 2507-2510. 
75 Nair, V.; Sinu, C. R.; Babu, B. P.; Varghese, V.; Jose, A.; Suresh, E. Org. Lett. 2009, 
11, 5570-5573. 
76 Maji, B.; Ji, L.; Wang, S.; Vedachalam, S.; Ganguly, R.; Liu, X.-W. Angew. Chem. Int. 
Ed. 2012, 51, 8276-8280. 
77 White, N. A.; DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2013, 135, 8504-8507. 
78 This was inspired by work from the Lupton group.  See: a) Pandiancherri, S.; Ryan, S. 
J.; Lupton, D. W. Org. Biomol. Chem. 2012, 10, 7903-7911. b) Ryan, S. J.; Candish, L.; 
Lupton, D. W. J. Am. Chem. Soc. 2011, 133, 4694-4697. 
79 When this is used as starting material, no conversion to desired product is observed. 
80 Chan, A.; Scheidt, K. A. Org. Lett. 2005, 7, 905-908. 
81 DiRocco, D. A.; Oberg, K. M.; Dalton, D. M.; Rovis, T. J. Am. Chem. Soc. 2009, 131, 
10872-10874. 
82 Castells, J.; López-Calahorra, F.; Bassedas, M.; Urrios, P. Synthesis 1988, 314-315. 
83 He, L.; Jian, T.-Y.; Ye, S. J. Org. Chem. 2007, 72, 7466-7468.  Also see: Chen, X.-Y.; 
Xia, F.; Ye, S. Org. Biomol. Chem. 2013, 11, 5722-5726. 
84 Atienza, R. L.; Scheidt, K. A. Aust. J. Chem. 2011, 64, 1158-1164. 
85 Dalton, D. M.; Rappé, A. K.; Rovis, T. Chem. Sci. 2013, 4, 2062-2070. Also see: a) 
Keller-Friedman, R.; Oberg, K. M.; Dalton, D. M.; Rovis, T. Pure Appl. Chem. 2010, 82, 
1353-1364. b) Dalton, D. M.; Oberg, K. M.; Yu, R. T.; Lee, E. E.; Perreault, S.; Oinen, M. 
E.; Pease, M. L.; Malik, G.; Rovis, T. J. Am. Chem. Soc. 2009, 131, 15717-15728. 
86 Hyster, T. K.; Rovis, T. Chem. Sci. 2011, 2, 1606-1610. 
87 Piou, T.; Rovis, T. J. Am. Chem. Sci. 2014 ASAP doi: 10.1021/ja506579t 
88 DiRocco, D. A.; Oberg, K. M.; Dalton, D. M.; Rovis, T. J. Am. Chem. Soc. 2009, 131, 
10872-10874. 
89 Please see: a) DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2011, 133, 10402-10405. 
b) DiRocco, D. A.; Noey, E. L.; Houk, K. N.; Rovis, T. Angew. Chem. Int. Ed. 2012, 51, 
2391-2394. c) Sánchez-Larios, E.; Thai, K.; Bilodeau, F.; Gravel, M. Org. Lett. 2011, 13, 
4942-4945. 
90 White, N. A.; DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2013, 135, 8504-8507. 
91 a) Rovis, T. Chem. Lett. 2008, 37, 2-7. b) Read de Alaniz, J.; Kerr, M. S.; Moore, J. L.; 
Rovis, T. J. Org. Chem. 2008, 73, 2033-2040. 
92 Vacca, J. P.; Dorsery, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; 
Zugay, J.; Quintero, J. C.; Blanhy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; 
Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Vastag, K.; 
Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. Proc. Natl. Acad. Sci. U.S.A. 1994, 
91, 4096. 
93 For a recent example , see: Behenna, D. C.; Mohr, J. T.; Sherden, N. H.; Marinescu, 
S. C.; Harned, A. M.; Tani, K.; Seto, M.; Ma, S.; Novák, Z.; Krout, M. R.; McFadden, R. 
M.; Roizen, J. L.; Enquist, Jr. J. A.; White, D. E.; Levine, S. R.; Petrova, K. V.; Iwashita, 
A.; Virgil, S. C.; Stoltz, B. M. Chem. Eur. J. 2011, 17, 14199-14223. 
	   80	  
94 For a recent example, see: Xiong, H.; Xu, H.; Liao, S.; Xie, Z.; Tang, Y. J. Am. Chem. 
Soc. 2013, 135, 7851-7854. 
95 For a recent example, see: Sibi, M. P.; Ito, K. J. Am. Chem. Soc. 2007, 129, 8064-
8065. 
96 a) Tanaka, T.; Katsumura, S. J. Am. Chem. Soc. 2002, 124, 9660-9661. b) 
Kobayashi, T.; Tanaka, K.; Miwa, J.; Katsumura, S. Tetrahedron: Asymmetry 2004, 15, 
185-188. c) Liu, S. Y.; Katsumura, S. Chin. Chem. Lett. 2009, 20, 1204-1206. d) 
Kobayashi, T.; Hasegawa, F.; Hirose, Y.; Tanaka, K.; Mori, H.; Katsumura, S. J. Org. 
Chem. 2012, 77, 1812-1832. 
97 Hsieh, S.-Y.; Binanzer, M.; Kreituss, I.; Bode, J. W. Chem. Commun. 2012, 48, 8892-
8894. 
98 Kuwano, S.; Harada, S.; Kang, B.; Oriez, R.; Yamaoka, Y.; Takasu, K.; Yamada, K.-i. 
J. Am. Chem. Soc. 2013, 135, 11485-11488. 
99 Hansen, M. M.; Borders, S. S. K.; Clayton, M. T.; Heath, P. C.; Kolis, S. P.; Larsen, S. 
D.; Linder, R. J.; Reutzel-Edens, S. M.; Smith, J. C.; Tameze, S. L.; Ward, J. A.; Weigel, 
L. O. Org. Proc. Res. Dev. 2009, 13, 198-208. 
100 Brand, J. P.; Osuna Siles, J. I.; Waser, J. Synlett 2010, 881-884. 
101 Zheng, P.; Gondo, C. A.; Bode, J. W. Chem. Asian. J. 2011, 6, 614-620. 
102 DiRocco, D. A.; Oberg, K. M.; Rovis, T. J. Am. Chem. Soc. 2012, 134, 6143-6145. 
103 Egert, M.; Walther, S.; Plenio, H. Eur. J. Org. Chem. 2014, 4362-4369. 
104 Bildstein, B.; Malaun, M.; Kopacka, H.; Ongania, K.-H.; Wurst, K. J. Organomet. 
Chem. 1999, 572, 177-187. 
105 For an example, see: a) Colotta, V.; Catarzi, D.; Varano, F.; Filacchioni, G.; Martini, 
C.; Trincavelli, L.; Lucacchini, A. Bioorg. Med. Chem. 2003, 11, 3541-3550. b) Abd 
Allah, S. O.; Ead, H. A.; Kassab, N. A.; Zayed, M. M. J. Heterocyclic Chem. 1983, 20, 
189-190. 
106 Jafarpour, L.; Stevens, E. D.; Nolan, S. P. J. Organomet. Chem. 2000, 606, 49-54. 
Also ref. 21 
107 a) Calder, I. C.; Spotswood, T. M.; Sasse, W. H. F. Tetrahedron Lett. 1963, 2, 95. b) 
Calder, I. C.; Sasse, W. H. F. Aust. J. Chem. 1965, 18, 1819. 
108 Würtz, S.; Glorius, F. Acc. Chem. Res. 2008, 41, 1523. 
109  See ref: 90a, 93  
110 Liu, G.; Wilkerson, P. D.; Toth, C. A.; Xu, H. Org. Lett. 2012, 14, 858-861. 
111 a) Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457. b) Martin, R.; Buchwald, S. L. 
Acc. Chem. Res. 2008, 41, 1461. 
112 Structure Elucidation accomplished by John Chu (CSU) 
113 Vora, H. U.; Lathrop, S. P.; Reynolds, N. T.; Kerr, M. S.; Read de Alaniz, J.; Rovis, T. 
Org. Synth. 2010, 87, 350. 
114 Schedler, M.; Fröhlich, R.; Daniliuc, C.-G.; Glorius, F. Eur. J. Org. Chem. 2012, 
4164-4171. 
115 a) Surry, D. S.; Buchwald, S. L. Chem. Sci. 2011, 2, 27-50. b) Ziegler, D. T.; Muñoz-
Molina, J. M.; Bissember, A. C.; Peters, J. C.; Fu, G. C. J. Am. Chem. Soc. 2013, 135, 
13107-13112. 
	  
	   81	  
APPENDIX 1 
 







All reactions were carried out under an atmosphere of argon with magnetic stirring.  
HPLC grade Chloroform preserved with pentane was purchased from Fisher Scientific. 
Column chromatography was performed on SiliCycle®SilicaFlash®  P60, 40-63µm 60A. 
Thin layer chromatography was performed on  SiliCycle® 250µm 60A plates.  
Visualization was accomplished with UV light or p-anisaldehyde stain followed by 
heating.  This stain is highly recommended, with starting material typically staining 
orange, intermediate as brown, and final product as a dark blue. 
 
1H NMR spectra were obtained on Varian 300 or  400 MHz spectrometers at ambient 
temperature.  Data is reported as follows:  chemical shift in parts per million (δ, ppm) 
from CDCl3 (7.26 ppm)  multiplicity (s = singlet, bs = broad singlet, d = doublet, t = 
triplet, q = quartet, and m = multiplet), coupling constants(Hz).   
13C NMR  was recorded on  Varian  300 or  400 MHz spectrometers (at 75 or 100 MHz) 
at  ambient temperature.  Chemical shifts are reported in ppm from CDCl3 (77.2 ppm)  
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Varian CP-3800 Gas Chromatograph was used to determine diastereomeric and 
enantiomeric ratios.  For the achiral column, Varian CP-Sil 8CB (15m X 0.25mm) was 
used.  For the chiral column, Chiraldex BDM-1 was used, unless otherwise stated. 
 
Aldehyde substrates were purchased from Sigma-Aldrich and subsequently distilled. 
 
 
Ketoesters were prepared according to literature precedent: 
17a,1 17h,2 17i,3 17j-17k,4 17l-17p,1 17q.5 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Runcie,	  K.	  A.;	  Taylor,	  R.	  J.	  K.	  Chem.	  Commun.	  2002,	  974-­‐975	  
2	  Schuda,	  P.	  F.;	  Ebner,	  C.	  B.;	  Potlock,	  S.	  J.	  Synthesis,	  1987,	  1055-­‐1057.	  
3	  Gérard,	  S.;	  Raoul,	  M.;	  Sapi,	  J.	  Eur.	  J.	  Org.	  Chem.	  2006,	  2440-­‐2445.	  
4	  Zigterman,	  J.	  L.;	  Woo,	  J.	  C.	  S.;	  Walker,	  S.	  D.;	  Tedrow,	  J.	  S.;	  Borths,	  C.	  J.;	  Bunel,	  E.	  E.;	  Faul,	  M.	  
M.	  J.	  Org.	  Chem.	  2007,	  72,	  8870-­‐8876.	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Amine catalyst 18 was prepared by literature reported method.6 
 
 




General procedure for synthesis of 21a: 
25 mg (0.17 mmol) of Keto-Ester 17a is added to an oven-dried 10mL round bottom 
flask.  11mg (0.2 equiv., 0.03 mmol) of amine catalyst 18 and 14 mg (0.2 equiv., 0.03 
mmol) of triazolium 9 are then added.  1 ml of CHCl3 is added and argon is bubbled into 
the mixture.  20 μl (1.2-1.5 equiv, 0.2 mmol) of butyraldehyde (16a) is then added, 
followed by 2.5mg (0.2 equiv, 0.03 mmol) of NaOAc.  The reaction is outfitted with a 
reflux condenser and stir bar, and heated to 60 °C for 12 hours.  Reaction is monitored 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6	  Marigo,	  M.;	  Wabnitz,	  T.	  C.;	  Fielenbach,	  	  D.;	  Jørgensen,	  K.	  A.	  Angew.	  Chem.	  Int.	  Ed.	  2005,	  44,	  
794-­‐797.	  
7	  Vora,	  H.	  U.;	  Lathrop,	  S.	  P.;	  Reynolds,	  N.	  T.;	  Kerr,	  M.	  S.;	  Read	  de	  Alaniz,	  J.;	  Rovis,	  T.	  Org.	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by silica gel TLC.  Upon completion, the reaction is cooled to room temperature and 
filtered through a small plug (1 in) of silica gel, washing with DCM then EtOAc.  The 
solution is concentrated and purified by column chromatography, eluting with 10% 
EtOAc/DCM to 50% EtOAc/Hexanes through silica gel.  Fractions were collected and 
concentrated to provide the desired product. 
 
 
(1S,2R,4S)-ethyl 2-ethyl-4-hydroxy-4-methyl-3-oxocyclopentanecarboxylate (21a) 
Rf= 0.3 (10% Ethyl Acetate/Dichloromethane); 28 mg (72%), 94% ee, 19:1:<1:<1 dr 
[α]D21 =  -40.83 (c = 0.0024 g/ml, CHCl3) GC Analysis CP-Sil 8CB column at 110 °C, 1 
ml/min. Major: 12.07min. Minor: 12.95 min, 13.84 min, 15.14 min. BDM-1 column at 130 
°C, 1 ml/min. Major: 24.35 min. Minor: 23.81 min.  1H NMR: (300 MHz; CDCl3):  δH 4.16-
4.23 (2 H, q), 2.98 (1 H, d, J 7.2), 2.33 (1 H, ddd, J =13.7, 7.2 and 0.3), 1.94 (1 H, d, J 
=10.5), 1.63 (1 H, d, J =7.3), 1.33 (3 H, d, J =0.8), 1.25-1.33 (3 H, t, J = 7.2 ), 0.92 (3 H, 
td, J =7.5 and 0.8)..13C NMR: (100 MHz, CDCl3) δ216.7, 174.8, 75.7, 60.9, 51.7, 42.3, 
39.3, 23.0, 22.1, 14.1, 10.8. IR (NaCl, neat): 3465, 2971, 2937, 2878, 1733, 1519, 1447, 
1378, 1298, 1234, 1177. HRMS: (ESI-) calcd for C12H20O4, 227.1289. Found 227.1291. 
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Rf= 0.3 (10% Ethyl Acetate/Dichloromethane); 28 mg (78%), 88% ee, 24:1.5:1 dr [α]D21 
=  -101.82(c = 0.0011 g/ml, CHCl3) GC Analysis CP-Sil 8CB column at 110 °C, 1 
ml/min. Major: 7.54min. Minor: 8.22, 9.46 min. BDM-1 column at 130 °C, 1 ml/min. 
Major: 17.33 min. Minor: 16.82 min.  1H NMR: (300 MHz, CDCl3) δ 4.20 (q, 2H), 2.84 (q, 
1H), 2.61 (m, 1H), 2.34 (dd, 1H), 1.94 (t, 1H), 1.35 (s, 3H), 1.29 (s, 3H), 1.24 (t, 3H).  
13C NMR: (100 MHz, CDCl3) δ 217.4, 174.5, 61.2, 46.07, 45.4, 39.3, 23.5, 14.4, 13.9. IR 
(NaCl, neat): 3436, 2980, 2938, 1732, 1520, 1450, 1376, 1181. HRMS: (ESI-) calcd for 
C11H26O4, 213.1249. Found 213.1256. 
 
(1S,2R,4S)-ethyl 4-hydroxy-4-methyl-3-oxo-2-propylcyclopentanecarboxylate(21c) 
Rf= 0.3 (10% Ethyl Acetate/Dichloromethane); 31 mg (76%), 95% ee, 33:1:1 dr [α]D21 = 
-56.97( c = 0.0033 g/ml, CHCl3) GC Analysis CP-Sil 8CB column at 110 °C, 1 ml/min. 
Major: 19.66min. Minor: 20.77, 22.00 min. BDM-1 column at 100 °C, 2 ml/min. Major: 
112.04 min. Minor: 113.74 min.  1H NMR: (300 MHz, CDCl3) δ 4.20 (q, 2H), 2.95 (q, 
1H), 2.66 (m, 1H), 2.33 (dd, 1H), 1.92 (m, 1H), 1.72 (m, 1H), 1.49 (m, 1H), 1.33 (s, 3H), 
1.28 (t, 3H), 0.90 (t, 3H).  13C NMR: (100 MHz, CDCl3) δ 217.3, 175.1, 61.2, 50.2, 43.4, 
39.7, 31.9, 23.2, 20.1, 14.4, 14.2. IR (NaCl, neat): 3448, 2964, 1734, 1377, 1178, 1038, 
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(1S,2R,4S)-ethyl 2-allyl-4-hydroxy-4-methyl-3-oxocyclopentanecarboxylate (21e) 
Rf = 0.39 (10% Ethyl Acetate/Dichloromethane); 37 mg (97%), 85% ee, 15:1:0.2:0.2 dr,  
[α]D21 = -67.23 (c = 0.0047 g/ml, CHCl3) GC Analysis: CP-Sil 8CB at 110 °C, 1 ml/min. 
Major 16.70 min. Minor: 18.16 min, 20.74 min, 21.11 min.  HPLC Analysis: ChiralPak IA 
column at 97% Hexanes/iPrOH, 1 ml/min. Major: 14.346 min. Minor: 12.338 min. 1H 
NMR: (300 MHz, CDCl3): δ  5.73-5.61 (m, 1H), 5.12-5.00 (m, 2H), 4.20-4.13 (m, 2H), 
2.98 (td, J = 10.3, 7.2 Hz, 1H), 2.77 (ddd, J = 10.2, 7.3, 4.8 Hz, 1H), 2.56-2.50 (m, 1H), 
2.33 (dtd, J = 13.6, 6.8, 1.9 Hz, 2H), 1.91 (ddd, J = 13.7, 10.4, 0.4 Hz, 1H), 1.33 (d, J = 
0.7 Hz, 3H), 1.33-1.24 (m, 3H). 13C NMR: (100 MHz, CDCl3): δ 216.0, 174.5, 134.3, 
117.7, 75.6, 60.9, 49.9, 42.2, 39.3, 33.4, 23.0, 14.1 IR (NaCl, neat): 3457, 2979, 2930, 
1734, 1641, 1520, 1444, 1378, 1227, 1179 cm-1. HRMS: (APCI+) Calc’d for C12H18O4, 
227.1278. Found 227.1276. 
 
 
(1S,2R,4S)-ethyl 2-benzyl-4-hydroxy-4-methyl-3-oxocyclopentanecarboxylate (21f) 
Rf = 0.21 (5% Ethyl Acetate/Dichloromethane); 25 mg (50%), 89% ee, 9:1:0.2:0.2 dr,  
[α]D21 = -126.92 (c = 0.0013 g/ml, CHCl3) HPLC Analysis Chiracel IC at 95% 
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7.14 (m, 5H), 3.98-3.83 (m, 2H), 3.19 (dd, J = 13.7, 4.5 Hz, 1H), 3.04-2.89 (m, 2H), 2.81 
(dd, J = 13.7, 7.2 Hz, 1H), 2.30-2.23 (m, 1H), 1.91-1.83 (m, 2H), 1.33 (s, 3H), 1.15-1.11 
(t, J = 7.0 Hz, 3H). 13C NMR: (100 MHz, CDCl3): δ 215.9, 174.6, 138.3, 129.55, 128.55, 
126.72, 75.8, 61.1, 52.5, 42.8, 39.7, 35.4, 23.1, 14.2. IR (NaCl, neat): 3442, 2980, 1732, 







Rf = 0.31 (5% Ethyl Acetate/Dichloromethane); 37mg (59%), 90% ee, 9:1:0.2:0.2 dr,  
[α]D21 = -42.61 (c = 0.0023 g/ml, CHCl3) HPLC Analysis Chiracel IC at 95% 
Hexanes/iProH. Major 13.64 min. Minor: 16.34 min 1H-NMR (300 MHz; CDCl3): δ  7.23 
(d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 4.36 (d, J = 4.0 Hz, 2H), 4.13 (dd, J = 11.6, 
7.1 Hz, 3H), 3.80 (s, 3H), 3.55 (td, J = 4.8, 2.1 Hz, 2H), 3.09 (d, J = 7.2 Hz, 1H), 2.78 (s, 
1H), 2.38-2.34 (m, 1H), 2.04 (d, J = 5.4 Hz, 3H), 1.88 (dd, J = 13.7, 10.6 Hz, 2H), 1.31 
(s, 3H), 1.23 (t, J = 7.1 Hz, 3H).13C NMR: (100 MHz, CDCl3): δ 216.5, 191.3, 180.5, 
174.5, 159.1, 130.0, 129.2, 113.8, 113.7, 72.4, 67.1, 60.9, 55.2, 47.7, 42.7, 39.8, 29.0, 
22.7, 14.1 IR (NaCl, neat): 3445, 2936, 1730, 1611, 1514, 1444, 1376, 1301, 1247, 












Rf= 0.24 (10% Ethyl Acetate/Dichloromethane); 38 mg (97%), 89% ee, 33:1:1:nd dr 
[α]D21 = -62.32 (c = 0.0043 g/ml, CHCl3) GC Analysis CP-Sil 8CB column at 110 °C, 1 
ml/min. Major: 8.33 min. Minor: 8.98, 9.51 min. BDM-1 column at 130 °C, 1 ml/min. 
Major: 18.72 min. Minor: 18.31 min.  1H NMR: (300 MHz, CDCl3) δ 3.7 (s, 3H), 2.99 (q, 
1H), 2.62 (m, 1H), 2.32 (dd, 1H), 1.93 (m, 1H), 1.77 (m, 1H), 1.63 (m, 2H), 1.33 (s, 3H), 
0.91 (t, 3H).  13C NMR: (100 MHz, CDCl3) δ 216.3, 175.6, 52.4, 52.1, 42.4, 39.6, 23.1, 
22.2, 10.9. IR 3456, 2970, 1737, 1439, 1377, 1170, 1032. HRMS: (ESI-) Calc’d for 
C10H16O4, 199.0976. Found 199.0979. 
 
 
(1S,2R,4S)-benzyl 2-ethyl-4-hydroxy-4-methyl-3-oxocyclopentanecarboxylate (21i) 
Rf= 0.31 (10% Ethyl Acetate/Dichloromethane); 24 mg (58%), 85% ee, 17:1 dr [α]D21 = -
65.38 (c = 0.0013 g/ml, CHCl3) GC Analysis CP-Sil 8CB column at 140 °C, 3 ml/min. 
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Hexanes/Isopropanol, 1ml/min. Major: 11.03 min. Minor: 9.89 min.  1H NMR: (300 MHz, 
CDCl3) δ 7.36 (bs, 5H), 5.18 (s, 2H), 3.06 (q, 1H), 2.65 (m, 1H), 2.32 (dd, 1H), 1.94 (m, 
1H), 1.62 (m, 2H), 1.32 (s, 3H), 0.89 (t, 3H).  13C NMR: (100 MHz, CDCl3) δ 216.7, 
174.9, 135.8, 128.8, 128.6, 128.4, 67.0, 51.9, 42.6, 39.5, 23.1, 22.3, 11.0. IR (NaCl, 
neat): 3448, 3034, 2969, 2935, 2878, 1734, 1455, 1385 cm-1. HRMS: (ESI-) calcd for 





Rf= 0.27 (50% Ethyl Acetate/Dichloromethane); 30 mg (70%), 97% ee, 8:1:0.3:0.1 dr, 
[α]D21 = -40.0 (c = 0.0017 g/ml, CHCl3) GC Analysis CP-Sil 8CB at 140 °C, 3 ml/min. 
Major: 12.52 min. Minor: 10.08min, 9.59 min,. BDM1 column at 170 °C, 3ml/min. Major: 
20.23 min. Minor: 19.75 min.  1H NMR: (300 MHz, CDCl3) δ 3.52 (quint, J = 6.6 Hz, 4H), 
3.08 (m, 1H), 2.94 (m, 1H), 2.25 (dd, J = 6.9 Hz, 1H), 1.97-1.81 (m, 5H), 1.71 (m, 2H), 
1.54 (m, 1H), 1.34 (s, 3H), 0.89 (t, J = 7.5 Hz, 3H).  13C NMR: (100 MHz, CDCl3) δ 
217.8, 172.3, 52.4, 46.8, 46.3, 42.1, 39.5, 26.2, 24.5, 23.4, 21.9, 11.3 IR (NaCl, neat): 
3354, 2969, 2876, 1746, 1622, 1518, 1452, 1343, 1255, 1229, 1165cm-1. HRMS: (ESI+) 












Rf= 0.30 (100% Ethyl Acetate); 37 mg (99%), 98% ee, 9:1:0.4:0.1 dr, [α]D21 = -44.23 (c 
= 0.0052 g/ml, CHCl3) GC Analysis CP-Sil 8CB at 140 °C, 3 ml/min. Major: 14.49 min. 
Minor: 12.83min, 12.01 min, 12.45 min. BDM1 column at 160 °C, 3ml/min. Major: 41.07 
min. Minor: 40.48 min.  1H NMR: (300 MHz, CDCl3) δ 3.68 (m, 8H), 3.17 (m, 1H), 3.01 
(m, 1H), 2.19 (dd, J = 6.9, 13.5 Hz, 1H), 1.81 (m, 2H), 1.55 (m, 1H), 1.33 (s, 3H), 0.89 (t, 
J = 7.5 Hz, 3H) 13C NMR: (100 MHz, CDCl3) δ 217.0, 191.3, 172.0, 75.84, 66.9, 51.8, 
45.9, 42.6, 39.8, 39.5, 23.1, 21.7, 11.1 IR (NaCl, neat): 3383, 2966, 1745, 1638, 1438, 
1240, 1117 cm-1. HRMS: (ESI+) Calcd for C13H22NO3, 240.1594. Found 240.1596. 
 
 
(1S,2R,4S)-ethyl 2,4-diethyl-4-hydroxy-3-oxocyclopentanecarboxylate (21l) 
Rf= 0.21 (10% Ethyl Acetate/Dichloromethane); 42 mg (76%), 81% ee, 55:1:1 dr [α]D21 = 
-56.82( c = 0.0022 g/ml, CHCl3) GC Analysis CP-Sil 8CB at 110 °C, 1 ml/min. Major: 
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min. Minor: 34.54 min.  1H NMR: (300 MHz, CDCl3) δ 4.20 (q, 2H), 2.94 (q, 1H), 2.61 
(m, 1H), 2.21 (dd, 1H), 1.99 (m, 1H), 1.78 (m, 1H), 1.60 (m, 3H), 1.29 (t, 3H), 0.92 (t, 
3H).  13C NMR: (100 MHz, CDCl3) δ 217.3, 175.2, 61.2, 52.6, 42.4, 36.7, 29.6, 21.9, 
14.4, 11.1, 7.8. IR (NaCl, neat): 3467, 2970, 2938, 2880, 1734, 1518, 1462, 1378, 1231, 





(1S,2R,4S)-ethyl 2-ethyl-4-hydroxy-3-oxo-4-propylcyclopentanecarboxylate (21m) 
Rf= 0.24 (10% Ethyl Acetate/Dichloromethane); 19 mg (53%), 85% ee, 16:1 dr [α]D21 = -
70.0 ( c = 0.0008 g/ml, CHCl3) GC Analysis CP-Sil 8CB at 110 °C, 1 ml/min. Major: 
32.66min. Minor: 35.76 min. BDM-1 column at 130 °C, 1 ml/min. Major: 55.68 min. 
Minor: 54.01 min.  1H NMR: (300 MHz, CDCl3) δ 4.20 (q, 2H), 2.95 (q, 1H), 2.60 (m, 
1H), 2.20 (dd, 1H), 2.02 (m, 1H), 1.79 (m, 1H), 1.60 (m, 3H), 1.50 (m, 2H) 1.29 (t, 3H), 
0.92 (m, 6H).  13C NMR: (100 MHz, CDCl3) δ 217.2, 175.1, 61.2, 52.5, 42.5, 38.9, 37.2, 
21.9, 16.9, 14.6, 14.4,11.1. IR (NaCl, neat): 3437, 2957, 2865, 1720, 1462, 1377, 1232, 
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(1S,2R,4R)-ethyl 2-ethyl-4-hydroxy-3-oxo-4-phenylcyclopentanecarboxylate (21o) 
Rf= 0.71 (10% Ethyl Acetate/Dichloromethane); 39 mg (95%), 83% ee, 4.4:1:<1:<1 dr 
[α]D21 = -62.50 (c = 0.002 g/ml, CHCl3) GC Analysis CP-Sil 8CB at 170 °C, 2 ml/min. 
Major: 6.40min. Minor: 6.50, 7.96, 7.86 min. HPLC Analysis : Chiralcel IC column 95:5 
Hexanes/Isopropanol, 1ml/min. Major: 9.43 min. Minor: 10.13 min.  1H NMR: (300 MHz, 
CDCl3) δ 7.35 (bs, 5H), 4.15 (m, 2H), 3.13 (q, 1H), 2.83 (m, 1H), 2.60 (dd, 1H), 2.30 (m, 
0.5H), 1.74 (m, 1H), 1.27 (q, 3H), 0.98 (t, 3H).  13C NMR: (100 MHz, CDCl3) δ 215.7, 
174.7, 141.2, 128.7, 128.2, 125.6, 61.3, 53.9, 42.8, 42.0, 22.0, 14.4, 11.0. IR (NaCl, 
neat): 3442, 3062, 2973, 2938, 2878, 1733, 1496, 1448, 1376 cm-1. HRMS: (ESI+) 





Rf= 0.3 (10% Ethyl Acetate/Dichloromethane); 24mg (58%), 68% ee, 9:1:0.4:0.6 dr, 
[α]D21 = -56.0 (c = 0.0025g/ml, CHCl3) GC Analysis [CP-Sil 8CB] at 110 °C, 1 ml/min. 
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98% Hexanes/Isopropanol, 1ml/min. Major: 33.32 min. Minor: 27.89 min.  1H NMR: (300 
MHz; CDCl3): δ  3.17 (td, J = 10.2, 7.4 Hz, 1H), 2.78-2.71 (m, 1H), 2.36 (dd, J = 13.5, 
7.4 Hz, 1H), 2.27 (s, 3H), 2.01-2.00 (m, 1H), 1.77-1.66 (m, 2H), 1.62-1.52 (m, 2H), 1.31 
(s, 3H), 0.88 (t, J = 7.5 Hz, 3H).13C NMR: (100 MHz, CDCl3): δ 217.1, 208.9, 75.9, 49.9, 
49.8, 39.4, 29.5, 22.9, 22.1, 11.0 IR (NaCl, neat): 3442, 2971, 2931, 1741, 1702, 1437, 





Rf= 0.12 (10% Ethyl Acetate/Dichloromethane); 12mg (35%), % ee, 4:1:0.4:0.6 dr, [α]D21 
= -104 (c = 0.003g/ml, CHCl3) GC Analysis: CP-Sil 8CB at 170 °C and 3 ml/min.  Major: 
25.108 min.  Minor: 26.679 min, 30.489 min, 35.243 min.  HPLC Analysis Chiracel IC 
column at 95% Hexanes/iPrOH, 1 ml/min. Major: 11.248 min. Minor 12.768 min. 1H 
NMR: (300 MHz; CDCl3): δ  7.41-7.27 (m, 5H), 3.33 (td, J = 11.0, 6.7 Hz, 1H), 2.95 (dt, 
J = 10.9, 5.6 Hz, 1H), 2.66-2.56 (m, 2H), 2.32-2.24 (m, 3H), 2.02 (ddd, J = 13.6, 11.5, 
2.0 Hz, 1H), 1.86-1.76 (m, 1H), 1.74-1.64 (m, 1H), 1.64-1.57 (m, 1H), 0.96-0.88 (m, 
3H).13C NMR: (100 MHz, CDCl3) δ215.9, 208.4, 140.9, 128.5, 128.0, 125.2, 80.2, 52.3, 
49.8, 41.9, 29.7, 21.7, 11.0  IR (NaCl, neat): 3410, 3061, 3029, 2966, 2934, 2877, 2252, 












In a 5 ml round bottom flask, 25 mg of 2a (0.17 mmol) was combined with 10 mg of 3 
(0.2 equiv, 0.03 mmol) and 1.7 μl of AcOH (0.2 equiv., 0.03 mmol) and dissolved in 1 ml 
of chloroform.  The reaction was stirred at 60 °C for 3 hours.  The reaction was cooled 
to room temperature and 14 mg of 6 (0.2 equiv., 0.03 mmol) and 5 mg of sodium 
acetate (0.4 equiv., 0.06 mmol) were added.  The reaction was stirred at 60 °C for an 
additional 4 hours.  The reaction was cooled to room temperature and filtered through a 
plug of silica gel, washing with DCM then EtOAc.  The filtrate was concentrated and 
purified by column chromatography, eluting with 10% EtOAc/DCM to 50% 
EtOAc/Hexanes through silica gel.  Isolated a yellow oil. 
 
Rf= 0.35 (10% Ethyl Acetate/Dichloromethane); 49 mg (90%), 88% ee, 24:1:0.1 dr, 
[α]D21 = -66.96 (c = 0.0046 g/ml, CHCl3) GC Analysis CP-Sil 8CB column at 90 °C, 2 
ml/min. Major: 24.48 min. Minor: 26.62 min, 27.69 min. BDM1 column at 130 °C, 
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6.9, 2H), 3.08 (q, J = 7.5, 1H), 2.72 (dd, J = 3.9, 9.9, 1H), 2.92 (dd, J = 7.5, 13.8, 1H), 
2.25 (m, 1H), 1.90 (m, 2H), 1.31 (s, 3H), 1.29 (t, J = 7.2, 3H), 0.97 (d, J = 6.9, 3H), 0.91 
(d, J = 6.9, 3H).  13C NMR: (100 MHz, CDCl3) δ 216.7, 175.7, 61.2, 56.7, 39.9, 39.6, 
27.9, 22.9, 20.3, 18.8, 14.3 IR (NaCl, neat): 3472, 2967, 2876, 1735, 1519, 1466, 1378, 






In a 5 ml round bottom flask, combined 25 mg of 2o (0.15 mmol) with 10 mg of 3 (0.2 
equiv., 0.03 mmol) and 11 mg of 5 (0.2 equiv., 0.03 mmol). Dissolved in 1 ml of CHCl3 
and bubbled Ar into the reaction mixture for 1 minute.  Added 20 μl of butyraldehyde 
(1a, 1.5 equiv., 0.22 mmol) and 2.5 mg of NaOAc (0.2 equiv., 0.03 mmol).  Stirred at 80 
°C for 4 hours.  Cooled to room temperature and filtered through a plug of silica gel, 
washing with DCM then EtOAc.  Concentrated the filtrate and purified by column 
chromatography, eluting with 10% EtOAc/DCM through 50% EtOAc/Hexanes through 
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Rf= 0.3 (10% Ethyl Acetate/Dichloromethane); 25 mg (69%), 51% ee, 18:1:0.1:0.7 dr, 
[α]D21 = -44.50 (c = 0.004 g/ml, CHCl3) GC Analysis CP-Sil 8CB at 110 °C, 1 ml/min. 
Major: 27.97min. Minor: 28.35 min, 30.41 min, 32.16 min. BDM1 column at 130 °C, 
2ml/min. Major: 26.85 min. Minor: 27.55 min.  1H NMR: (300 MHz, CDCl3) δ 4.21 (q, J = 
7.2, 2H), 2.93 (q, J = 7.2, 1H), 2.54 (q, J = 5.7, 1H), 2.01 (m, 3H), 1.83 (m, 2H), 1.60 (m, 
1H), 1.29 (t, J = 6.9, 3H), 0.98 (d, J = 6.9, 3H), 0.90 (t, J = 7.5, 3H), 0.83 (d, J = 6.9, 3H).  
13C NMR: (100 MHz, CDCl3) δ 217.6, 175.2, 81.4, 61.2, 53.9, 42.2, 33.4, 33.3, 21.5, 
17.7, 16.2, 14.4, 10.9 IR (NaCl, neat): 3467, 2967, 2878, 1735, 1466, 1377, 1233, 1180 




(1S,2R,3S,4S)-ethyl 2-ethyl-3,4-dihydroxy-4-methylcyclopentanecarboxylate (7) 
In a 5 ml round bottom flask, 25 mg (0.17 mmol) of 2a was combined with 10 mg of 3 
(0.2 equiv., 0.03 mmol) and 14 mg of 6 (0.2 equiv., 0.03 mmol).  This mixture was taken 
up in CHCl3 and bubbled with Ar for 1 minute.  18 μl of butyraldehyde (1a, 1.2 equiv., 
0.2 mmol) and 2.5 mg of NaOAc (0.2 equiv, 0.03 mmol) were added and the reaction 
was stirred at 60 °C for 5 hours.  The reaction was cooled to room temperature and 40 
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suspension was stirred at room temperature overnight.  The reaction mixture was 
filtered through silica gel, eluting with EtOAc.  The filtrate was concentrated and purified 
by column chromatography, eluting with 100% EtOAc through silica gel.  Isolated a 
yellow oil. 
 
Rf= 0.22 (100% Ethyl Acetate); 31mg (84%), 88% ee, 35:1:<1:<1 dr, [α]D21 = -67.33 (c = 
0.0015 g/ml, CHCl3) GC Analysis CP-Sil 8CB at 130 °C, 1 ml/min. Major: 8.69min. 
Minor: 5.6 min, 7.33 min, 5.12 min. BDM1 column at 120 °C, 2ml/min. Major: 62.36 min. 
Minor: 61.63 min.  1H NMR: (300 MHz, CDCl3) δH 4.13 (2 H, q, J 7.0, A), 3.55 (1 H, d, J 
6.8, B), 2.60 (1 H, d, J 8.7, C), 1.99 (3 H, m, J 8.7, D), 1.65 (1 H, d, J 7.4, E), 1.54 (1 H, 
d, J 7.3, F), 1.31 (3 H, sG), 1.22-1.27 (3 H, mH), 0.94 (3 H, t, J 7.4, I). 13C NMR: (100 
MHz, CDCl3) δC 176.0, 84.4, 80.1, 60.6, 51.2, 44.5, 41.3, 26.5, 22.9, 14.1, 11.8 IR 
(NaCl, neat): 3421, 2964, 2934, 2877, 1729, 1519, 1458, 1376, 1179 cm-1. HRMS: 




(2S,3R)-ethyl 3-formyl-2-(2-oxopropyl)pentanoate (20) 8 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  






















	   98	  
In a 5 ml round bottome flask, combined 200 mg of 2a (1.41 mmol) with 45 mg of 3 (0.1 
equiv, 0.14 mmol).  Dissolved in 6 ml of CHCl3 and 1 ml of MeOH, added 0.15 ml of 
butyraldehyde (1a, 1.2 equiv., 1.69 mmol) and 2 drops of acetic acid.  Stirred at 60 °C 
for 5 hours.  Cooled to room temperature and concentrated.  Purified by column 
chromatography, eluting with 10% EtOAc/Hexanes through silica gel.  Isolated as a 
mixture of diastereomers.  Product is a yellow oil. 
 
Rf= 0.45 (10% Ethyl Acetate/Dichloromethane); 301mg (99%), 96% ee, 1.1:1 dr, [α]D21 = 
+20.8 (c = 0.005 g/ml, CHCl3) GC Analysis.  1H NMR: (300 MHz, CDCl3) δH  9.65 (1 H, 
s), 4.10-4.18 (2 H, m), 3.29-3.39 (1 H, m), 2.97 (1 H, ddd, J 25.6, 17.9 and 9.3), 2.53-
2.59 (1 H, m), 2.36-2.53 (1 H, m), 2.17-2.22 (3 H, s), 1.70-1.80 (1 H, m), 1.40-1.54 (2 H, 
m), 1.22-1.32 (3 H, m), 0.94-1.00 (3 H, m). 13C NMR: (100 MHz, CDCl3) δ206.3, 206.1, 
202.4, 191.3, 178.7, 18.3, 173.2, 172.9, 61.1, 54.1, 47.8, 47.4, 41.9, 41.5, 41.3, 39.3, 
30.0, 29.9, 22.7, 21.9, 19.4, 14.0, 12.0,  IR (NaCl, neat): 2971, 2881, 1720, 1463, 1369, 
1165, 1045 cm-1. HRMS: (ESI+) calcd for C11H19O4, 215.1278. Found 215.1270. 
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NMR Studies 
In a 1 dram vial, 25 mg of 20 (0.12 mmol) was combined with 9 mg of 9 (0.2 equiv, 0.02 
mmol), 2 mg of NaOAc (0.2 equiv., 0.02 mmol), and 7 mg trimethoxybenzene (internal 
standard, 0.3 equiv., 0.04 mmol).  This mixture was taken up in CDCl3 and transferred 
to an NMR tube.  The tube was heated in an oil bath at 60 °C.  Spectra was taken at 
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Crossover Experiments 
 
To determine if a retro-Michael was responsible for low diastereoselectivity, a crossover 
experiment was conducted by heating the intermediate aldehyde 20d with 
butyraldehyde in the presence of the amine catalyst.  No crossover product was 





To determine if the NHC catalyst played a role in the retro-Michael, compound 20n was 
exposed to catalyst 9, base, and heat for one day.  The combination of the bulky 
isopropyl-ketone and a chiral catalysts prevents the benzoin cyclization.  If the retro-
Michael occurred, we would expect formation of starting material 17a.  None was 






























1:1 dr Not Observed




In case the combination of the amine catalyst and the NHC catalyst was responsible, 
S11 was exposed to both catalysts, isovaleraldehyde, and heat for 1 day.  No crossover 
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APPENDIX 2 
 









21i was combined with 10% Palladium on Carbon (10 wt%) and suspended in dry 
methanol.  An atmosphere (1 atm) of H2 was introduced via balloon and stirred at room 
temperature overnight.  The reaction was filtered through a plug of celite and 
concentrated to an oil.  This crude oil was then dissolved in DCM and the amine (1 
equiv.) was added.  The reaction was concentrated and the product was recrystallized 
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 Table 1.  Crystal data and structure refinement for Rovis99_0m. 
Identification code  rovis99_0m 
Empirical formula  C17H25NO4 
Formula weight  307.38 
Temperature  120 K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.1775(5) Å a= 90°. 
 b = 13.7872(10) Å b= 90°. 
 c = 19.8051(14) Å g = 90°. 
Volume 1686.8(2) Å3 
Z 4 
Density (calculated) 1.210 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 664 
Crystal size 0.20 x 0.11 x 0.06 mm3 
Theta range for data collection 1.80 to 24.41°. 
Index ranges -7<=h<=7, -15<=k<=16, -23<=l<=23 
Reflections collected 24929 
Independent reflections 2773 [R(int) = 0.1599] 
Completeness to theta = 24.41° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9950 and 0.9835 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2773 / 0 / 204 
Goodness-of-fit on F2 1.005 
Final R indices [I>2sigma(I)] R1 = 0.0559, wR2 = 0.1031 
R indices (all data) R1 = 0.1341, wR2 = 0.1311 
Absolute structure parameter -1(2) 
Largest diff. peak and hole 0.191 and -0.253 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for Rovis99_0m.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 1189(7) 5403(3) 2272(2) 36(1) 
C(2) 2746(7) 5442(3) 1665(2) 32(1) 
C(3) 1591(7) 4816(3) 1137(2) 30(1) 
C(4) 442(7) 4023(3) 1557(2) 25(1) 
C(5) -428(7) 4592(3) 2162(2) 30(1) 
C(6) 3355(10) 6445(3) 1442(2) 56(2) 
C(7) -1185(7) 3485(3) 1119(2) 23(1) 
C(8) -945(8) 4013(4) 2802(2) 44(1) 
C(9) 849(9) 3380(3) 3045(2) 53(2) 
C(10) 6989(8) 4591(3) 9518(2) 33(1) 
C(11) 6401(8) 5494(3) 9768(2) 38(1) 
C(12) 7823(9) 6258(3) 9735(2) 43(1) 
C(13) 9829(9) 6134(4) 9452(2) 46(1) 
C(14) 10428(8) 5231(3) 9207(2) 36(1) 
C(15) 9024(7) 4455(3) 9239(2) 25(1) 
C(16) 9717(6) 3510(3) 8924(2) 23(1) 
C(17) 8800(7) 3376(3) 8215(2) 30(1) 
N(1) 9017(5) 2659(2) 9347(1) 22(1) 
O(1) 1297(5) 5923(2) 2760(2) 47(1) 
O(2) 4568(5) 4940(2) 1949(2) 45(1) 
O(3) -396(4) 2840(2) 731(1) 24(1) 
O(4) -3154(5) 3710(2) 1143(1) 27(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for Rovis99_0m. 
_____________________________________________________ 
C(1)-O(1)  1.206(5) 
C(1)-C(5)  1.514(6) 
C(1)-C(2)  1.540(6) 
C(2)-O(2)  1.437(5) 
C(2)-C(6)  1.499(6) 
C(2)-C(3)  1.532(6) 
C(3)-C(4)  1.545(5) 
C(4)-C(7)  1.521(6) 
C(4)-C(5)  1.530(5) 
C(5)-C(8)  1.532(6) 
C(7)-O(4)  1.256(5) 
C(7)-O(3)  1.272(5) 
C(8)-C(9)  1.490(6) 
C(10)-C(15)  1.386(6) 
C(10)-C(11)  1.388(6) 
C(11)-C(12)  1.373(6) 
C(12)-C(13)  1.371(7) 
C(13)-C(14)  1.387(6) 
C(14)-C(15)  1.379(5) 
C(15)-C(16)  1.506(5) 
C(16)-N(1)  1.505(4) 



































Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for Rovis99_0m.  The anisotropic 
displacement factor exponent takes the form: -2p2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 28(3)  40(3) 40(3)  -14(3) -1(2)  12(3) 
C(2) 30(3)  26(3) 39(3)  -10(2) -5(2)  2(2) 
C(3) 31(3)  33(3) 28(2)  -2(2) 1(2)  5(2) 
C(4) 22(3)  29(3) 24(2)  -6(2) 2(2)  3(2) 
C(5) 22(3)  36(3) 33(3)  -15(2) 1(2)  -1(2) 
C(6) 79(4)  40(3) 50(3)  -7(3) 8(3)  -15(3) 
C(7) 28(3)  21(3) 19(2)  3(2) -2(2)  -7(2) 
C(8) 43(3)  64(4) 25(3)  -10(2) -3(2)  1(3) 
C(9) 65(4)  57(4) 37(3)  0(3) 1(3)  -10(3) 
C(10) 39(3)  26(3) 33(3)  4(2) -1(2)  3(3) 
C(11) 42(3)  35(3) 38(3)  1(2) 11(3)  4(3) 
C(12) 66(4)  20(3) 43(3)  -3(2) -4(3)  12(3) 
C(13) 52(4)  29(3) 58(3)  -1(3) 2(3)  -10(3) 
C(14) 40(3)  29(3) 39(3)  -4(2) 4(2)  -4(3) 
C(15) 26(3)  22(3) 27(2)  2(2) 0(2)  2(2) 
C(16) 19(2)  22(2) 29(2)  3(2) 4(2)  -4(2) 
C(17) 35(3)  36(3) 20(2)  5(2) 4(2)  -1(2) 
N(1) 23(2)  22(2) 21(2)  -4(2) 3(2)  4(2) 
O(1) 34(2)  57(2) 49(2)  -32(2) 2(2)  -2(2) 
O(2) 27(2)  54(2) 54(2)  -29(2) -7(2)  8(2) 
O(3) 26(2)  24(2) 23(2)  -8(1) -2(1)  6(2) 
O(4) 19(2)  27(2) 34(2)  -10(1) 1(1)  0(2) 
______________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for Rovis99_0m. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(3A) 2622 4530 826 36 
H(3B) 551 5196 884 36 
H(4) 1530 3560 1718 30 
H(5) -1783 4897 2017 36 
H(6A) 4503 6407 1117 84 
H(6B) 3831 6814 1826 84 
H(6C) 2121 6755 1242 84 
H(8A) -1322 4464 3159 53 
H(8B) -2204 3611 2716 53 
H(9A) 2190 3732 3026 80 
H(9B) 945 2815 2763 80 
H(9C) 570 3187 3502 80 
H(10) 6017 4077 9539 39 
H(11) 5038 5582 9958 46 
H(12) 7424 6861 9905 51 
H(13) 10785 6654 9424 56 
H(14) 11796 5148 9019 43 
H(16) 11301 3505 8895 28 
H(17A) 7248 3403 8233 46 
H(17B) 9245 2759 8040 46 
H(17C) 9329 3883 7927 46 
H(1A) 7626 2533 9269 33 
H(1B) 9201 2798 9782 33 
H(1C) 9809 2142 9239 33 
H(2) 5129 4598 1659 67 
________________________________________________________________________________ 
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APPENDIX 3 




Materials and Methods 
 
All reactions were carried out under an atmosphere of argon with magnetic stirring.  
Column chromatography was performed on SiliCycle®SilicaFlash®  P60, 40-63µm 60A. Thin layer 
chromatography was performed on SiliCycle® 250µm 60A plates.  Visualization was accomplished with 
UV light or KMnO4 stain followed by heating.   
 
1H NMR spectra were obtained on Varian 300 or  400 MHz spectrometers at ambient temperature.  Data 
is reported as follows:  chemical shift in parts per million (δ, ppm) from CDCl3 (7.26 ppm)  multiplicity (s = 
singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, and m = multiplet), coupling constants(Hz).   
 
13C NMR  was recorded on  Varian  300 or  400 MHz spectrometers (at 75 or 100 MHz) at  ambient 
temperature.  Chemical shifts are reported in ppm from CDCl3 (77.2 ppm)  
 
Enantioselectivity was determined by chiral HPLC (Agilent 1100) using Chiralpak IC column (Daicel).  
Samples were eluted with 98:2 Hexanes/iPrOH at 0.5mL/min.  Mass spectrometry was accomplished with 
an Agilent 6130 Quadropole MS with an Agilent 1200 LC system.  Infrared Spectrometry was gathered 
with a Thermo Scientific Nicolet iS50 FT-IR. 
 
Cinnamaldehyde 3 was purchased from Sigma-Aldrich and purified by vacuum distillation and 
subsequently stored in the refrigerator.  Other enals used were obtained from commercial sources 
(Sigma-Aldrich, Alfa-Aesar).  Aminal 27 was synthesized according to literature methods.1  Related 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Chi, Y.; Gellman, S. H. J. Am. Chem. Soc. 2006, 128, 6804-6805. 
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aminals were constructed analogously with the appropriate amine or solvent.  HPLC grade methanol is 







Representative procedure for the aminomethylation of enals: 
 
To a dry, 1 dram vial is added 99 mg of aminal 27 (0.44 mmol, 1.2 equiv.), 14 mg of NHC 29 (0.04 mmol, 
0.1 equiv.), and 30 mg of NaOAc (0.37 mmol, 1 equiv.).  Methanol (2 mL) is added, followed by 
cinnamaldehyde (50 mg, 0.37 mmol, 1 equiv.) and a magnetic stir bar.  The vial is sealed by screw cap 
and stirred at room temperature for 8h.  Upon reaction completion (judged by TLC) trimethoxybenzene (6 
mg, 0.037 mmol, 0.1 equiv) is then added to the reaction and stirred for 30 min.  The reaction mixture is 
filtered through a plug of silica gel, washing with DCM, then EtOAc.  The organic phase is concentrated in 
vacuo.  NMR is used to judge reaction completion (84% yield).  The crude reaction mixture can be purifed 
by column chromatography, eluting with 20-50% EtOAc/Hexane through silica gel.  Isolated 91mg of a 
yellow oil (65% isolated yield). 
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84% (NMR) rf = 0.6 (20% EtOAc/Hexane) 
1H-NMR (300 MHz; CDCl3): δ 7.38 (s, 3H), 7.24 (t, J = 6.0 Hz, 11H), 7.04 (d, J = 6.8 Hz, 2H), 3.68 (d, J = 
9.1 Hz, 2H), 3.62 (s, 1H), 3.54 (s, 3H), 3.48 (d, J = 13.7 Hz, 2H), 3.40 (s, 1H), 2.87 (dd, J = 15.7, 5.8 Hz, 
1H), 2.56 (d, J = 7.7 Hz, 2H), 2.37 (dd, J = 15.7, 8.9 Hz, 1H).  13C-NMR (101 MHz; CDCl3): δ 173.1, 142.7, 
139.3, 128.9, 128.31, 128.15, 127.7, 126.9, 126.6, 59.4, 58.6, 51.4, 40.3, 38.8.  MS: calcd for C25H27NO2 
Expect: 373.49 Found: 374.2 (M+H).  IR (neat): 3060, 3026, 2947, 2786, 2360, 1733, 1674, 1602, 1494, 
1451, 1365, 1255, 1167, 1122, 974, 745 cm-1 
 
  
Methyl 4-(dibenzylamino)-3-(4-nitrophenyl)butanoate (28b) 
78% (NMR) rf = 0.4 (20% EtOAc/Hexane) 
1H-NMR (400 MHz; CDCl3): δ  8.08 (d, J = 8.6 Hz, 2H), 7.30-7.25 (m, 13H), 7.16-7.12 (m, 4H), 3.84 (s, 
1H), 3.62 (t, J = 6.7 Hz, 3H), 3.56 (s, 2H), 3.50 (d, J = 13.5 Hz, 2H), 2.80 (dd, J = 16.1, 5.8 Hz, 1H), 2.60 
(dt, J = 12.1, 6.3 Hz, 2H), 2.38 (dd, J = 16.0, 9.0 Hz, 1H).  13C-NMR (101 MHz; CDCl3): δ 172.2, 150.6, 
146.7, 139.7, 138.8, 128.95, 128.85, 128.6, 128.22, 128.11, 127.1, 126.7, 123.5, 72.3, 58.82, 58.72, 56.1, 
51.7, 40.3, 38.4.  MS: calcd for C25H26N2O4 Expect: 418.48 Found 419.2 (M+H).  IR (neat): 3061, 3026, 
2947, 2796, 2360, 1734, 1599, 1518, 1493, 1451, 1345, 1253, 1169, 1122, 1072, 973, 855, 745, 697 cm-1 
 
Ethyl 3-(4-chlorophenyl)-4-(dibenzylamino)butanoate (36c2) 
88% (NMR) rf = 0.6 (20% EtOAc/Hexane) 
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1H-NMR (400 MHz; CDCl3): δ  7.27 (dd, J = 15.4, 7.9 Hz, 12H), 7.09 (d, J = 8.3 Hz, 2H), 4.02 (tt, J = 7.1, 
3.5 Hz, 2H), 3.57-3.51 (m, 2H), 3.47-3.36 (m, 2H), 2.87 (dd, J = 15.7, 5.9 Hz, 1H), 2.49-2.44 (m, 3H), 2.25 
(s, 3H), 1.15 (t, J = 7.1 Hz, 3H).  13C-NMR (101 MHz; CDCl3): δ 173.2, 157.2, 155.7, 138.6, 136.7, 129.7, 
128.8, 128.4, 128.2, 127.5, 125.7, 120.6, 120.1, 118.0, 110.8, 60.3, 59.1, 55.3, 51.8.   MS: calcd for 
C20H24ClNO2  Expect: 345.86  Found: 346.2 (M+H).  IR (neat) 3026, 2979, 2842, 2790, 1735, 1683, 1492, 




Methyl 4-(benzyl(methyl)amino)-3-(2-hydroxyphenyl)butanoate (28d) 
66% (NMR) rf = 0.5 (20% EtOAc/Hexane) 
1H-NMR (400 MHz; CDCl3): δ  7.30-7.25 (m, 0H), 7.08 (t, J = 7.6 Hz, 2H), 6.91 (d, J = 8.0 Hz, 1H), 6.82 
(d, J = 7.5 Hz, 1H), 6.76 (t, J = 7.4 Hz, 1H), 3.97 (d, J = 13.3 Hz, 2H), 3.77-3.69 (m, 2H), 3.66 (s, 3H), 
3.63 (s, 1H), 3.41 (d, J = 13.3 Hz, 2H), 2.77-2.65 (m, 4H).  13C-NMR (101 MHz; CDCl3): δ 173.2, 155.7, 
139.7, 136.7, 130.4, 129.7, 129.0, 128.4, 128.1, 127.9, 127.5, 125.6, 120.1, 118.1, 60.4, 59.1, 51.8, 36.8, 
34.2.  MS: calcd for C19H23NO3 Expect: 389.49 Found: 390.2 (M+H).  IR (neat): 3060, 3026, 2947, 2799, 
2360, 1770, 1734, 1602, 1493, 1452, 1364, 1252, 1164, 1120, 1027, 736 cm-1 
 
 
Methyl 4-(benzyl(methyl)amino)-3-phenylbutanoate (36) 
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1H-NMR (400 MHz; CDCl3): δ 7.29-7.16 (m, 10H), 3.58 (s, 3H), 3.52 (d, J = 21.3 Hz, 2H), 3.46 (s, 2H), 
2.94 (dd, J = 15.6, 6.1 Hz, 1H), 2.58 (d, J = 9.6 Hz, 1H), 2.52 (dd, J = 15.5, 8.6 Hz, 2H), 2.24 (s, 3H).  13C-
NMR (101 MHz; CDCl3): δ 173.1, 142.8, 138.99, 138.97, 129.0, 128.4, 128.1, 127.5, 126.9, 126.6, 63.3, 
62.8, 51.4, 42.3, 40.3, 39.0.  MS: calcd C19H23NO2 Expect: 297.39 Found: 298.2 (M+H).  IR (neat): 3027, 
2948, 2841, 2788, 1702, 1602, 1494, 1452, 1435, 1356, 1255, 1195, 1163, 1022, 739, 697 cm-1 
 
 
Methyl 4-(dibenzylamino)-3-(4-methoxyphenyl)butanoate (28f) 
70% (NMR) rf = 0.6 (20% EtOAc/Hexane) 
1H-NMR (400 MHz; CDCl3): δ  7.48 (d, J = 8.2 Hz, 1H), 7.30-7.23 (m, 9H), 6.97 (d, J = 8.6 Hz, 2H), 6.80 
(d, J = 8.6 Hz, 2H), 3.79 (s, 3H), 3.67 (s, 1H), 3.63 (d, J = 5.9 Hz, 3H), 3.55 (s, 3H), 3.50 (s, 2H), 2.87 (dd, 
J = 15.6, 5.8 Hz, 1H), 2.54 (dd, J = 7.7, 3.3 Hz, 2H), 2.33 (dd, J = 15.6, 9.1 Hz, 1H).  13C-NMR (101 MHz; 
CDCl3): δ 173.1, 158.2, 139.7, 139.3, 134.8, 128.96, 128.89, 128.6, 128.1, 126.8, 113.7, 59.5, 58.6, 56.1, 
55.2, 51.4, 39.4, 39.0.  MS: calcd for C26H29NO3 Expect: 403.51 Found: 404.2 (M+H).  IR (neat): 3060, 
3026, 2948, 2833, 2796, 2359, 1734, 1603, 1494, 1452, 1247, 1167, 1028, 828, 745, 698 cm-1 
 
Methyl 4-(dibenzylamino)-3-(2-methoxyphenyl)butanoate (28g) 
84% (NMR) rf = 0.5 (20%EtOAc/Hexanes) 
1H-NMR (300 MHz; CDCl3): δ  7.29-7.18 (m, 11H), 7.06 (d, J = 1.4 Hz, 1H), 6.88-6.82 (m, 2H), 3.91-3.83 
(m, 1H), 3.82-3.79 (m, 1H), 3.77 (s, 3H), 3.57 (s, 3H), 3.53-3.47 (m, 1H), 2.88 (dd, J = 15.5, 6.7 Hz, 1H), 
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128.4, 128.2, 127.8, 127.5, 125.7, 120.6, 120.1, 118.0, 110.8, 60.3, 59.20, 59.06, 55.3, 51.8, 51.4, 37.6, 
36.9, 34.2.  MS:  calcd for C20H25NO3  Expect: 327.42  Found: 328.2 (M+H).  IR (neat): 3061, 3027, 2947, 
2836, 2794, 1724, 1697, 1599, 1492, 1452, 1243, 1163, 1026, 749, 698 cm-1. 
 
Methyl 4-(allyl(benzyl)amino)-3-phenylbutanoate (36h) 
74% (NMR) rf = 0.6 (20% EtOAc/Hexane) 
1H-NMR (300 MHz; CDCl3): δ7.39-7.19 (m, 9H), 7.13-7.10 (m, 1H), 5.86-5.76 (m, 1H), 5.17-5.11 (m, 2H), 
3.74-3.69 (m, 1H), 3.56 (s, 3H), 3.43 (d, J = 13.7 Hz, 2H), 3.18 (dd, J = 14.1, 5.7 Hz, 1H), 3.00-2.92 (m, 
1H), 2.95-2.87 (m, 1H), 2.58-2.53 (m, 2H), 2.45 (dd, J = 15.6, 8.6 Hz, 1H).  13C-NMR (101 MHz; CDCl3): δ 
195.3, 173.2, 144.8, 142.9, 139.3, 135.7, 128.91, 128.87, 128.3, 128.10, 128.05, 127.6, 126.8, 126.5, 
117.5, 56.9, 51.4, 40.3, 38.8.  MS: calcd for C21H25NO2 Expect: 323.43 Found: 324.2 (M+H).  IR (neat): 
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To a 1.5 dram vial was added enal (50 mg, 0.378 mmol, 1.0 equiv) and aminal followed by sodium 
acetate (0.378 mmol, 1.0 equiv), NHC 65 (0.076 mmol, 0.2 equiv), and TFE (0.2 M, 2 mL).  A magnetic 
stir bar was added and the reaction mixture was allowed to stir for 24-48 h. TLC was taken to confirm 
completion.  The mixture was then filtered through a silica gel plug and washed with dichloromethane, 
then EtOAc.  The filtrate was collected and concentrated.  The crude mixture was then purified by column 
chromatography (100% DCM ! 50% EtOAc/Hexane) to provide the product.   
 
Representative Spectral Data 
 
 
(E)-2-((benzyl(methyl)amino)methyl)-3-phenylacrylaldehyde (56)  
Prepared according to the general procedure: 94% yield; yellow oil; Rf=0.35 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.65 (d, J = 3.84, 1H), 7.89 (m, J = 3.88, 1.64, 2H), 7.67 (m, J = 3.86, 1.96, 
1H), 7.49-7.41 (m, 5H), 7.31-7.24 (m, 6H), 3.54 (s, 2H), 3.42 (s, 2H), 2.16 (d, J = 4.99, 
3H); 13C-NMR (101 MHz; CDCl3): δ 195.2, 194.1, 155.7, 154.4, 139.1, 138.9, 134.6, 131.3, 130.9, 130.35, 
130.27, 129.14, 129.09, 128.96, 128.65, 128.47, 128.2, 127.0, 62.2, 50.2, 41.8.  LRMS (ESI+) calcd for 




99% yield; yellow oil; Rf=0.48 (8:2 hex/EtOAc);  
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7.45-7.22 (m, 9H), 3.507 (s, 2H), 3.362 (s, 2H), 2.144 (d, J = 7.79, 3H); 13C-NMR (101 MHz; CDCl3): δ 
194.9, 152.9, 139.1, 138.8, 133.0, 132.6, 129.1, 128.9, 128.2, 127.1, 62.2, 50.8, 50.0, 41.8.  LRMS 




53% yield; yellow oil; Rf=0.33 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.67 (m, 1H), 7.97 (d, J = 8.31, 2H), 7.66 (s, 1H), 7.671 (d, J =8.38, 2H), 
7.29 (m, 6H), 3.521 (s, 2H), 3.362 (s, 2H), 2.163 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 194.5, 151.0, 
141.3, 138.65, 138.52, 132.5, 132.2, 131.5, 130.5, 129.2, 128.3, 127.3, 62.4, 49.8, 42.0.  LRMS (ESI+) 




72% yield; yellow oil; Rf=0.33 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.69 (d, J = 7.30, 1H), 8.34-8.20 (m, 3H), 8.07-8.02 (m, 2H), 7.85-7.82 (m, 
1H), 7.49-7.42 (m, 1H), 7.39-7.24 (m, 6H), 3.533 (s, 2H), 3.371 (s, 2H), 2.175 (s, 3H); 13C-NMR (101 
MHz; CDCl3): δ 194.4, 150.4, 141.7, 140.5, 138.4, 131.8, 130.8, 129.2, 128.3, 127.3, 124.0, 123.6, 62.4, 
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(E)-2-((benzyl(methyl)amino)methyl)-3-(4-(trifluoromethyl)phenyl)acrylaldehyde (56d) 
63% yield; yellow oil; Rf=0.48 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.67 (d, J = 6.50, 1H), 8.00 (d, J = 8.16, 1H), 7.70 (m, 3H), 7.45 (s, 1H), 
7.274 (m, 4H), 3.53 (s, 2H), 3.38 (s, 2H), 2.17 (m, 3H); 13C-NMR (101 MHz; CDCl3): δ 194.7, 193.5, 
153.1, 151.8, 140.7, 138.7, 131.3, 130.3, 129.1, 128.3, 127.2, 125.85, 125.81, 125.48, 125.44, 63.0, 62.2, 




40% yield; yellow oil; Rf=0.38 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.58 (m, 1H), 7.89-7.86 (m, 2H), 7.36-7.23 (m, 8H), 6.95-6.92 (m, 3H), 3.53 
(m, 2H), 3.40 (d, J = 4.44, 2H), 2.16 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 195.3, 154.8, 139.2, 136.6, 
133.6, 129.2, 128.2, 127.0, 114.1, 62.1, 55.4, 50.8, 50.2, 41.8, 29.7  LRMS (ESI+) calcd for C19H21NO2, 
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1H-NMR (300 MHz, CDCl3): δ 9.63 (d, J = 5.97, 1H), 7.78 (d, J = 8.49, 2H), 7.55 (m, 3H), 7.29 (s, 5H), 
3.517 (s, 2H), 3.35 (m, 2H), 2.145 (s, 3H);  13C-NMR (101 MHz; CDCl3): δ 194.9, 152.9, 139.3, 132.8, 





88% yield; yellow oil; Rf=0.39 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.72 (s, 1H), 8.25-8.22 (m, 1H), 7.75-7.68 (m, 1H), 7.65 (m, J = 8.00, 1H), 
7.38-7.22 (m, 8H), 3.48 (s, 2H), 3.32 (s, 2H), 2.10 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 194.7, 152.4, 
140.0, 138.8, 136.6, 134.0, 133.0, 130.1, 129.7, 129.1, 128.2, 127.0, 122.9, 62.0, 50.3, 41.3.  LRMS 




43% yield; yellow oil; Rf=0.26 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.62 (s, 1H), 7.77 (t, J = 9.11, 2H), 7.62-7.54 (m, 2H), 7.38-7.25 (m, 8H), 
3.54 (s, 2H), 3.39 (d, J = 3.58, 2H), 2.13 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 194.7, 152.4, 140.0, 
138.8, 136.6, 134.0, 133.0, 130.1, 129.7, 129.1, 128.2, 127.0, 122.9, 62.0, 50.3, 41.3.  LRMS (ESI+) 
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(E)-ethyl 4-(benzyl(methyl)amino)-3-formylbut-2-enoate (56j) 
53% yield; yellow oil; Rf=0.05 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.00 (s, 1H), 7.38 (m, 4H), 7.23 (m, J = 8.39, 6.96, 3H), 6.95 (s, 1H), 4.504 
(m, 2H), 4.113 (q, J = 7.13, 3H), 3.463 (s, 2H), 3.091 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 207.0, 129.1, 




96% yield; yellow oil; Rf=0.58 (8:2 hex/EtOAc);  
1H-NMR(300 MHz, CDCl3): δ 9.56 (s, 1H), 7.73 (m, 2H), 7.56-7.20 (m, 15H), 5.29 (m, 
3H), 3.52 (m, J = 2.46, 6H); 13C-NMR (101 MHz; CDCl3): δ 195.4, 153.7, 139.1, 138.5, 131.4, 130.2, 




72% yield; yellow oil; Rf=0.56 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.59 (s, 1H), 7.91-7.84 (m, 2H), 7.68 (m, 1H), 7.57-7.35 (m, 5H), 7.35-7.21 
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138.8, 135.5, 131.3, 130.36, 130.21, 129.2, 129.0, 128.5, 128.1, 126.9, 118.0, 58.4, 57.1, 47.4.  LRMS 




50% yield; yellow oil; Rf=0.41 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.63 (s, 1H), 7.89 (s, 2H), 7.43 (s, 4H), 7.24 (t, J = 7.16, 2H), 6.84 (d, J = 
8.45, 2H), 3.79 (s, 3H), 3.44 (d, 4H), 2.14 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 195.3, 158.7, 154.3, 
138.9, 134.6, 131.3, 131.1, 130.28, 130.26, 128.6, 61.6, 55.2, 50.0, 41.7  LRMS (ESI+) calcd for 




75% yield; light yellow oil; Rf=0.15 (8:2 hex/EtOAc);  
1H-NMR (300 MHz, CDCl3): δ 9.64 (s, 1H), 7.86 (m, J = 5.83, 2H), 7.48-7.44 (m, 4H), 3.69 (t, 
J = 4.65, 4H), 3.32 (s, 2H) 2.49 (t, J = 4.65, 4H); 13C-NMR (101 MHz; CDCl3): δ 194.9, 154.7, 138.1, 
134.6, 131.1, 130.3, 128.7, 67.0, 53.2, 50.8.  LRMS (ESI+) calcd for C14H17NO2, 231.29. 
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APPENDIX 4 
EXPERIMENTAL AND SPECTRAL DATA FOR CHAPTER 4 
 
 
Materials and Methods: 
 
Instrumentation:  
Thin Layer chromatography was performed with SiliCycle 250 μm 60A plates.  Visualization by UV light 
(254 nm) or treatment with I2 or KMnO4 was effective.  Flash column chromatography was conducted with 
aluminum oxide (Sigma-Aldrich, activated, basic, Brockmann I). 
NMR studies were conducted on a Varian 400 MHz spectrometer or Varian 300 MHz spectrometer at 
ambient temperature.  1H-NMR is recorded as follows: Chemical shifts (δ, ppm), multiplicity, coupling 
constant, and integration.  13C-NMR is recorded as chemical shifts (δ, ppm).  Mass Spectrometry was 
achieved with an Agilent Technologies 6130 Quadropole LC/MS.  Infrared Spectrometry was achieved 
with a Thermo Scientific Nicolet iS50 FT-IR. 
 
Materials: 
Boronic acids were purchased from Sigma-Aldrich or AKSci.  Trityl salts were purchased from Sigma-
Aldrich or Oakwood Chemicals.  Palladium catalyst was purchased from Sigma-Aldrich.  NHC catalysts 
were prepared according to literature procedures.  Solvents were obtained from VWR and purified through 
aluminum oxide column.  HPLC grade water was used as well.  No solvent was degassed.  CDCl3 and 
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General Procedure for Reduction of Triazolium salt to Triazoline 
 
In a 50 mL round-bottomed flask with a magnetic stir bar, the triazolium salt (1.83 mmol, 1 equiv.) is 
dissolved in DCM (10 mL) and cooled to 0 °C by ice-water bath.  After 10 minutes, sodium borohydride 
(69 mg, 1.83 mmol, 1 equiv) is carefully added.  This is followed by 1 ml of Ethanol, where upon the 
reaction bubbles vigorously.  The reaction is continued to stir at 0 °C for 3-4 hours.  The reaction is diluted 
with DCM (20 mL) and washed with water (2 X 15 mL).  The aqueous fractions are combined and 
extracted with DCM (20 mL).  The DCM fractions are dried over MgSO4, filtered, and concentrated.  
Crude product is typically pure enough to continue, but can easily be purified by flash column 
chromatography (0 to 50% EtOAc/Hexanes through basic Al2O3). 
 
	  
2-phenyl-3,5,6,7-tetrahydro-2H-pyrrolo[2,1-c] [1,2,4]triazole (28a) 
 
282 mg of light brown solid (82% yield from 500 mg SM). rf = 0.5 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; acetone-D6): δ 7.22-7.17 (m, 2H), 6.89-6.85 (m, 2H), 6.75 (d, J = 7.4 Hz, 1H), 4.62 (s, 
2H), 3.07 (t, J = 6.4 Hz, 2H), 2.45-2.35 (m, 4H).  13C-NMR (101 MHz; acetone-D6): δ 162.1, 148.3, 128.7, 




















151 mg of light brown oil (98% yield from 200 mg SM).  rf = 0.55 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; CDCl3): δ 7.32 (s, 2H), 4.70 (s, 2H), 3.10 (t, J = 6.5 Hz, 2H), 2.51 (dd, J = 6.7, 1.3 Hz, 
2H), 2.44-2.39 (m, 2H).  13C-NMR (101 MHz; CDCl3): δ 162.9, 139.6, 137.6, 135.8, 132.4, 129.5, 129.22, 






74 mg (99% yield from 200mg SM). rf = 0.6 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; CDCl3): δ 4.74 (s, 2H), 3.09 (t, J = 6.5 Hz, 2H), 2.54 (m, 2H), 2.43 (m, 2H). 13C-NMR 
(101 MHz; acetone): δ 164.2, 139.31, 139.27, 137.5, 135.1, 73.3, 46.8, 25.3, 19.0  MS: calcd for 
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136 mg of light brown solid (84% yield from 200mg of SM). rf = 0.65 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; acetone-d6): δ 10.50 (d, J = 0.3 Hz, 1H), 4.82 (t, J = 7.4 Hz, 2H), 3.46 (t, J = 7.7 Hz, 
2H), 3.04 (t, J = 7.5 Hz, 2H).13C-NMR (101 MHz; acetone): δ163.51, 163.50, 138.4, 129.21, 129.12, 
128.56, 128.39, 126.5, 72.9, 61.8, 41.2, 32.0, 19.8. MS. calcd for C18H14F5N3 Expect: 367.32 Found: 
368.1 (M+H).  IR: (neat) 3028, 2939, 2848, 1649, 1500, 1455, 1366,1294, 1193, 1041, 992, 825 cm-1.  






139 mg of white solid (85% yield from 200mg of SM).  rf = 0.6 (50% EtOAc/Hexane)  
1H-NMR (400 MHz; acetone-d6): δ  7.44 (d, J = 7.1 Hz, 1H), 7.33-7.25 (m, 3H), 5.56 (d, J = 1.4 Hz, 1H), 
5.00 (s, 1H), 4.72 (q, J = 5.0 Hz, 1H), 4.58 (d, J = 15.6 Hz, 1H), 4.49 (d, J = 5.4 Hz, 1H), 4.44 (d, J = 15.6 
Hz, 1H), 3.23 (dd, J = 7.3, 5.2 Hz, 2H).13C-NMR (101 MHz; acetone): δ 149.0, 140.8, 140.4, 128.3, 126.9, 
125.2, 124.7, 76.9, 73.52, 73.48, 73.43, 62.2, 59.2, 35.2. MS: calcd for C18H12F5N3O Expect 381.30 
Found 382.10 (M+H). IR: (neat) 2913, 1627, 1502, 1459, 1429, 1337, 1311, 1297, 1280, 1147, 1098, 
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General Procedure for Oxidation by Trityl Salts. 
 
A dry, 5 mL round-bottomed flask is equipped with a magnetic stir bar.  The triazoline (1 equiv.) is added 
to this flask, dissolved in DCM (0.2 M), and an Ar atmosphere is introduced.  The desired Trityl salt (1 
equiv.) is added in one portion.  The reaction is stirred at room temperature for overnight, and completion 
is judged by TLC.  Typically, addition of Et2O causes precipitation of the desired triazolium salt, which is 
recovered by filtration.   
	  
	  
2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium hexafluorophosphate(V) (29b) 
 
128 mg of white solid (73% yield from 100 mg SM) rf: 0.1 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-D6): δ 10.36 (s, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.70-7.67 (m, 3H), 4.68 (t, J = 
7.4 Hz, 2H), 3.37 (t, J = 7.7 Hz, 2H), 2.98 (t, J = 7.5 Hz, 2H). 13C NMR (101 MHz; acetone): δ 163.8, 
137.8, 130.7, 121.1, 47.6, 26.8, 21.4. MS calcd for PF6: (-)144.96 Found: (-)145.1. IR: (neat) 3153, 2359, 
2341, 1595, 831 cm-1 
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179 mg of pale, purple solid (65% yield from 100 mg SM). rf = 0.12 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; CD3OD): δ 10.39 (s, 1H), 7.87 (d, J = 8.1 Hz, 2H), 7.65-7.62 (m, 3H), 4.50 (t, J = 7.4 
Hz, 2H), 3.25 (d, J = 7.7 Hz, 2H), 2.87 (t, J = 7.5 Hz, 2H). 13C NMR (101 MHz; CD3OD): δ 163.4, 137.6, 
135.9, 130.4, 129.9, 120.6, 26.4, 21.1. MS calcd for SbCl6: (-)334.48 Found: (-)334.8  IR: (neat) 2360, 
2341, 1590, 1388, 762 cm-1 
	  
	  
2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium perchlorate (29d) 
 
70mg of brown solid (46% yield from 100 mg SM). rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-d6): δ 10.38 (s, 1H), 7.94-7.91 (m, 2H), 7.69-7.66 (m, 3H), 4.68 (t, J = 7.4 Hz, 
2H), 3.37 (t, J = 7.7 Hz, 2H), 2.98 (t, J = 7.4 Hz, 2H).  13C NMR (101 MHz; acetone-d6): δ 164.2, 163.7, 
138.0, 130.6, 130.2, 121.1, 47.6, 26.8, 21.5.  MS calcd for C11H12N3+ Expect 186.23 Found 186.1 (M+).  IR: 
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1H-NMR (400 MHz; acetone-d6): δ 10.38 (s, 1H), 7.94 (s, 2H), 4.83 (t, J = 7.4 Hz, 2H), 3.45 (t, J = 7.8 Hz, 
2H), 3.03 (t, J = 7.5 Hz, 2H). 13C NMR (101 MHz; acetone): δ164.7, 143.1, 138.8, 134.2, 129.4, 48.6, 
26.7, 21.7. MS calcd for C11H19Cl3N3+ Expect: 289.57 Found 290.0 (M+) calcd for PF6- Expect:-144.96 






105 mg of white solid (71% yield from 89 mg SM). rf= 0.1 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; acetone-d6): δ 10.34 (s, 1H), 7.84 (d, J = 9.1 Hz, 2H), 7.21 (d, J = 9.1 Hz, 2H), 4.68 (t, 
J = 7.4 Hz, 2H), 3.92 (s, 2H), 3.37 (t, J = 7.7 Hz, 2H), 2.99 (t, J = 7.4 Hz, 2H). 13C-NMR (101 MHz; 
acetone): δ 163.5, 161.3, 137.3, 129.26, 129.09, 128.2, 122.9, 115.1, 55.3, 47.5, 26.7, 21.4 MS: calcd for 
C12H14N3O: (+) 216.26, Found (+)216.26; calcd for PF6: (-) 144.6, Found (-) 145.0. IR: (neat) 3651, 3152, 
2975, 2348, 1590, 1530, 1465, 1393, 1306, 1258, 1176, 1044, 977, 950 cm-1.  
	  
 
2-(perfluorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium hexafluorophosphate(V) (29g) 
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61 mg of beige solid (53% yield from 74 mg SM). rf = 0.1 (50% EtOAc/Hexane)  
1H-NMR (300 MHz; acetone-d6): δ 10.50 (d, J = 0.3 Hz, 1H), 4.82 (t, J = 7.4 Hz, 2H), 3.46 (t, J = 7.7 Hz, 
2H), 3.04 (t, J = 7.5 Hz, 2H). 13C-NMR (101 MHz; acetone): δ 165.0, 144.5, 143.61, 143.60, 143.55, 
142.8, 138.1, 48.7, 26.8, 21.7. MS: calcd for C11H7F5N3+ Expect: 276.18 Found 276.0 (M+) calcd for PF6- 





149 mg of light brown solid (79% yield from 136mg of SM). rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; acetone-d6): δ 10.02 (s, 1H), 7.41-7.39 (m, 5H), 5.51-5.46 (m, 1H), 3.58 (dd, J = 13.8, 
7.3 Hz, 1H), 3.44 (m, 3H), 3.19-3.12 (m, 1H), 2.92-2.85 (m, 1H). 13C-NMR: (101 MHz; acetone): δ 164.4, 
142.82, 142.80, 135.5, 129.3, 129.10, 128.98, 127.6, 63.4, 39.2, 32.8, 21.4 . MS: calcd for C18H14F5N3+ 
Expect: 366.31 Found: 366.10 (M+) calcd for PF6- Expect: -144.96 Found: -145.0. IR: (neat) 3139, 1600, 
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111 mg of white solid (59% yield from 139 mg of SM). rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; acetone-d6):  δ 11.33 (s, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.45 (dd, J = 6.7, 0.5 Hz, 2H), 
7.37-7.35 (m, 1H), 6.38 (d, J = 3.9 Hz, 1H), 5.44 (d, J = 16.5 Hz, 1H), 5.27 (d, J = 16.5 Hz, 1H), 5.21 (d, J 
= 4.7 Hz, 1H), 3.56 (dd, J = 17.3, 5.3 Hz, 1H), 3.31 (d, J = 17.1 Hz, 1H). 13C-NMR(101 MHz; acetone): δ 
151.8, 146.19, 146.18, 140.9, 135.1, 129.7, 127.2, 125.6, 125.0, 124.2, 77.3, 62.6, 59.9, 37.0. MS: calcd 
for C18H11F5N3O+ Expect 380.29 Found 380.30 (M+) calcd for PF6- Expect: -144.96 Found -145.0. IR: 
(neat) 2913, 1627, 1502, 1459, 1429, 1337, 1311, 1297, 1280, 1147, 1098, 1064, 1053, 973 cm-1.   [α]D23 






















     DCM
2) C6F5NHNH2
3) (EtO)3CH, PhCl
     120 °C
4) NaBH4
    DCM/EtOH, 0 °C
36 37
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Bromolactam 36 (2.09 g, 7.81 mmol, 1 equiv.), prepared according to Bode,2 is 
dissolved in CH2Cl2 (40 mL) in a dry flask 100mL round-bottom flask.  Trimethyloxonium 
tetrafluoroborate (1.15g, 7.81 mmol, 1 equiv.) is added, the flask is flushed with Ar, and 
the reaction is stirred at room temperature overnight.  After aliquot NMR indicates 
complete consumption of starting material, pentafluorophenylhydrazine (1.55 g, 7.81 
mmol, 1 equiv.) is added and the reaction is stirred overnight.  The reaction is monitored 
by aliquot NMR, and after completion CH2Cl2 is removed by rotary evaporator.  The 
crude hydrazide is then taken up in chlorobenzene (30 mL) and triethylorthoformate (5 
mL) and the reaction is stirred at 120 °C for 2 days.  After the reaction is determined to 
be complete by NMR, solvent and triethylorthoformate is removed in vacuo.  The crude 
product is then dissolved in a 10:1 DCM/EtOH solution (30 mL) and cooled to 0 °C by 
ice-water bath.  Sodium borohydride is added (295 mg, 7.81 mmol, 1 equiv.) and the 
reaction is stirred at 0°C for 5 hours.  Water is added carefully, and after gas evolution 
has ceased, the reaction is extracted with DCM (2 X 30 mL).  The organic layer is dried 
over MgSO4, filtered, and concentrated.  The crude product is purified by flash column 
chromatography, eluting with 0 to 50% EtOAc/Hexane through basic alumina.  Isolated 
2.02g of a light brown solid (56% yield).3 
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Hsieh, S.-Y.; Binanzer, M.; Kreituss, I.; Bode, J. W. Chem. Commun. 2012, 48, 8892-8894. 
3	  Based upon: Vora, H. U.; Lathrop, S. P.; Reynolds, N. T.; Kerr, M. S.; Read de Alaniz, J.; Rovis, T. Org. Synth. 
2010, 87, 350.	  





2.02 g (56% yield) of light brown solid.  rf = 0.5 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; aceton-d6): δ 7.63 (dd, J = 0.8, 0.4 Hz, 1H), 7.46 (dd, J = 8.1, 1.9 Hz, 1H), 7.29 (d, J 
= 8.1 Hz, 1H), 5.65 (t, J = 1.0 Hz, 1H), 5.00 (t, J = 1.0 Hz, 1H), 4.72 (d, J = 4.9 Hz, 1H), 4.59 (d, J = 15.7 
Hz, 1H), 4.55 (d, J = 5.2 Hz, 1H), 4.46 (d, J = 15.7 Hz, 1H), 3.20 (d, J = 4.7 Hz, 2H).  13C-NMR (101 MHz; 
acetone): δ 148.9, 143.7, 139.9, 131.2, 127.8, 127.1, 120.0, 77.1, 73.6, 62.2, 59.6, 35.1. MS: calcd for 
C18H11BrF5N3O Expect: 460.20 Found 462.0 (M+2H). IR (neat): 3273, 2916, 1698, 1653, 1521, 1471, 
1402, 1324, 1247,1215, 1075, 1026, 993 cm-1. [α]D23 = -81.8(c = 1, acetone) 
	  
General Procedure for Suzuki-Miyaura reaction with Triazolines. 
 
In a glove box, a dry 2-dram glass vial is loaded with PdCl2(PPh3)2 (7 mg, 0.01 mmol, 0.05 equiv.).  The 
vial is sealed and removed from the glove box.  To this vial is added triazoline (100 mg, 0.22 mmol, 1 
equiv.), arylboronic acid (0.32 mmol, 1.5 equiv.) and potassium phosphate tribasic (93 mg, 0.44 mmol, 2 
equiv.).  Dry THF (1.5 mL) is added followed by water (0.5 mL), as well as a magnetic stir bar.  The vial is 
sealed, secured with Teflon tape, and heated by oil bath at 60 °C for 6-12 h.  Reaction is deemed 























Pd(PPh3)2Cl2 (5 mol %)
K3PO4
THF/H2O, 60 °C
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reaction.  The aqueous fraction is removed, and the organic layer is dried over MgSO4.  The crude 
reaction product is filtered and concentrated.  The crude product is purified by flash column 






60 mg of dark brown solid (60% yield). rf = 0.5 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; acetone-d6): δ 7.70-7.60 (m, 4H), 7.47-7.35 (m, 4H), 5.68-5.67 (m, 1H), 5.04 (t, J = 
1.1 Hz, 1H), 4.78 (dd, J = 5.6, 1.1 Hz, 1H), 4.64-4.55 (m, 2H), 4.47 (d, J = 15.6 Hz, 1H), 3.30-3.28 (m, 
2H).  13C-NMR (101 MHz; acetone-d6): δ149.0, 141.6, 140.9, 140.3, 139.6, 129.82, 129.73, 128.49, 
128.44, 128.38, 127.8, 127.25, 127.18, 127.16, 126.8, 125.6, 123.8, 123.2, 77.1, 73.6, 62.3, 59.2, 34.8.  
MS calcd for C24H16F5N3O: 457.4, found 458.1 (M+H).  IR: (neat) 2914, 1626, 1504, 1479, 1429, 1340, 
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triazolo[4,3-d][1,4]oxazine (38b) 
 
72 mg of light brown solid (64% yield). rf = 0.7 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-D6): δ 7.99-7.92 (m, 2H), 7.85 (d, J = 8.4 Hz, 1H), 7.58-7.42 (m, 7H), 5.60-
5.60 (m, 1H), 5.00 (t, J = 1.1 Hz, 1H), 4.85-4.82 (m, 1H), 4.65 (d, J = 15.5 Hz, 2H),  
4.49 (d, J = 15.6 Hz, 1H), 3.36 (s, 2H).  13C NMR (101 MHz; acetone-D6): δ 149.1, 140.0, 139.7, 134.0, 
131.6, 130.1, 128.3, 127.6, 126.9, 126.16, 126.06, 125.8, 125.55, 125.39, 125.2, 77.1, 62.3, 59.3, 35.2.  
MS calcd for C28H18F5N3O: 507.45, Found: 508.20 (M+H) IR: (neat) 2913, 1700, 1503, 1428, 1338, 1312, 





b][1,2,4]triazolo[4,3-d][1,4] oxazine (38c) 
 
74 mg of light brown solid (66% yield). rf = 0.5 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-D6): δ 7.66 (t, J = 0.8 Hz, 1H), 7.55 (dd, J = 7.9, 1.7 Hz, 1H),  
7.37 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 2.2 Hz, 1H), 7.18 (d, J = 2.2 Hz, 1H), 7.16 (d, J = 2.2 Hz, ),  
7.01 (d, J = 8.3 Hz, 1H), 5.66 (m, 1H), 5.03 (t, J = 1.1 Hz, 1H), 4.77 (td, J = 5.8, 4.0 Hz, 1H),  
4.61 (d, J = 15.5 Hz, 1H), 4.54 (d, J = 5.3 Hz, 1H), 4.46 (d, J = 15.6 Hz, 1H), 3.87 (s, 4H), 3.84 (s, 4H), 
3.26 (dd, J = 11.9, 5.2 Hz, 2H).  13C-NMR (101 MHz; acetone-D6): δ 180.4, 177.5, 149.2, 141.5, 140.3, 
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C26H20F5N3O3 Expect: 517.45 Found 518.10 (M+H) IR: (neat) 2999, 2837, 1700, 1521, 1488, 1250, 1174, 






64 mg of brown solid (57% yield). rf = 0.5 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-d6): δ  7.67 (d, J = 0.8 Hz, 1H), 7.58-7.55 (m, 4H), 7.49 (td, J = 5.5, 2.0 Hz, 
3H), 7.40 (s, 1H), 5.67 (d, J = 1.3 Hz, 1H), 5.04 (d, J = 1.1 Hz, 1H), 4.77 (s, 2H), 4.60 (d, J = 15.5 Hz, 1H), 
4.54 (d, J = 5.3 Hz, 1H), 4.47-4.43 (m, 1H), 3.36 (d, J = 3.3 Hz, 1H), 3.26 (dd, J = 11.0, 5.2 Hz, 2H), 1.35 
(s, 9H).  13C-NMR (101 MHz; acetone): δ 150.0, 149.1, 141.6, 140.2, 139.3, 138.0, 127.1, 126.61, 126.43, 
125.62, 125.58, 123.1, 77.1, 73.6, 62.3, 59.2, 34.9, 30.7. MS: calcd for C28H24F5N3O Expect: 513.40 
Found 514.20 (M+H).  IR: (neat) 2963, 2905, 1698, 1517, 1364, 1269, 1112, 1076, 993 cm -1  [α]D23 = -

























35 mg of red solid (67% yield).4 rf = 0.5 (50% EtOAc/Hexanes) 
1H-NMR (300 MHz; acetone-d6):  δ 7.39-7.38 (m, 2H), 7.27-7.25 (m, 5H), 5.61 (d, J = 2.2 Hz, 1H), 5.00 (t, 
J = 1.1 Hz, 1H), 4.78 (q, J = 5.0 Hz, 1H), 4.62 (d, J = 15.6 Hz, 1H), 4.56 (d, J = 5.3 Hz, 1H), 4.46 (d, J = 
15.6 Hz, 1H), 3.29 (t, J = 4.6 Hz, 2H), 2.24 (s, 3H). 13C-NMR (101 MHz; acetone): δ 149.1, 141.7, 140.97, 
140.89, 139.0, 135.0, 130.2, 129.6, 129.3, 127.2, 125.8, 125.3, 125.0, 77.0, 73.5, 62.2, 59.3, 35.0, 19.7   
MS: calcd for C25H18F5N3O Expect: 471.42 Found 472.10. IR: (neat) 2918, 1701, 1627, 1503, 1428, 1339, 






41 mg of off-white solid (63% yield).3  rf = 0.45 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-D6): δ 8.28 (s, 2H), 8.02-7.96 (m, 2H), 7.77 (dd, J = 7.9, 1.8 Hz, 1H), 7.52 (d, 
J = 7.8 Hz, 1H), 5.69 (dd, J = 2.3, 1.3 Hz, 1H), 5.00 (dt, J = 2.2, 1.1 Hz, 1H), 4.80 (td, J = 5.6, 4.2 Hz, 1H), 
4.65-4.46 (m, 4H), 3.33 (dd, J = 7.3, 5.0 Hz, 2H).  13C NMR (101 MHz; acetone-D6): δ 149.0, 143.5, 
142.2, 141.6, 137.1, 131.8, 127.9, 127.56, 127.53, 126.1, 123.9, 120.67, 120.63, 120.61, 77.1, 73.7, 62.4, 
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59.3, 35.0 MS: calcd for C26H14F11N3O Expect: 593.39 Found: 594.10 (M+H).  IR: (neat) 2971, 2348, 






26 mg of light orange solid (48% yield).3 rf = 0.5 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; acetone-d6): δ 7.60 (s, 2H), 7.45 (d, J = 3.6 Hz, 2H), 7.16-7.10 (m, 2H), 5.62 (d, J = 
2.0 Hz, 1H), 5.02 (t, J = 1.0 Hz, 1H), 4.79 (q, J = 5.0 Hz, 1H), 4.65-4.57 (m, 2H), 4.47 (d, J = 15.6 Hz, 1H), 
3.31-3.28 (m, 2H). 13C-NMR (101 MHz; acetone-d6): δ149.7, 149.2, 141.5, 140.3, 138.9, 133.8, 127.0, 
125.5, 122.9, 119.2, 112.28, 112.25, 111.1, 110.8, 77.1, 73.6, 62.3, 59.2, 55.30, 55.28, 55.26, 34.8  MS 
calcd for C24H14F7N3O Expect: 493.38 Found 494.10 (M+H) IR (neat) 2937, 2837, 1700, 1504, 1465, 
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d][1,4]oxazin-2-ium tetrafluoroborate (39a) 
 
46 mg of off-white solid (65% yield). rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-d6):  δ 11.32 (s, 1H), 7.88 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 7.4 
Hz, 2H), 7.54 (d, J = 7.9 Hz, 1H), 7.43 (d, J = 7.9 Hz, 2H), 7.36 (d, J = 7.3 Hz, 1H), 6.42 (d, J = 4.2 Hz, 
1H), 5.43 (d, J = 16.4 Hz, 1H), 5.31-5.24 (m, 2H), 3.60 (dd, J = 17.2, 5.1 Hz, 1H), 3.35 (d, J = 17.2 Hz, 
1H).  13C-NMR (101 MHz; acetone): δ 151.7, 144.1, 140.5, 140.0, 136.0, 129.3, 128.9, 128.4, 127.5, 
126.9, 126.0, 122.9, 77.6, 62.6, 60.0, 36.7 MS calcd for C24H15F5N3O+ Expect: 456.39 Found: 456.1(M+).  
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(5aS,10bR)-9-(naphthalen-1-yl)-2-(perfluorophenyl)-4,5a,6,10b-tetrahydroindeno[2,1-
b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoroborate (39b) 
 
44 mg of off-white solid (37% yield). rf =0.1 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-d6): δ  11.27 (s, 1H), 8.00-7.94 (m, 2H), 7.82-7.80 (m, 1H), 7.74 (s, 1H), 7.63 
(d, J = 7.7 Hz, 1H), 7.54 (td, J = 7.9, 1.4 Hz, 3H), 7.47-7.39 (m, 3H), 6.49 (d, J = 4.1 Hz, 1H), 5.46 (d, J = 
16.4 Hz, 1H), 5.33-5.29 (m, 2H), 3.68 (m, 1H), 3.44-3.41 (m, 1H). 13C-NMR (101 MHz; acetone): δ 151.8, 
140.06, 139.94, 139.3, 135.6, 134.0, 131.43, 131.37, 129.3, 128.53, 128.35, 127.9, 127.0, 126.3, 125.9, 
125.66, 125.60, 125.41, 122.4, 77.6, 62.7, 60.1, 36.9.   MS calcd for C28H17F5N3O+ Expect: 506.45; 
Found: 506.1 (M+). IR (neat) 3058, 1698, 1594, 1550, 1529, 1482, 1394, 1250, 1075,1003, 861, 800, 780 




b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoroborate (39c) 
 
91 mg of light brown solid (99% yield). rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; aceton-d6):  δ 7.83 (s, 1H), 7.71-7.68 (m, 1H), 7.51-7.48 (m, 1H), 7.31-7.16 (m, 5H), 
7.01 (d, J = 8.3 Hz, 1H), 6.40-6.39 (m, 1H), 5.43 (d, J = 16.4 Hz, 1H), 5.31-5.23 (m, 2H), 3.58 (dd, J = 
17.1, 4.5 Hz, 1H), 3.33 (d, J = 17.2 Hz, 1H). 13C-NMR(101 MHz; acetone): δ 151.6, 149.8, 149.4, 140.5, 
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55.3, 36.7 MS: calcd for C26H19F5N3O3+ Expect 516.41 Found: 516.10 (M+) IR (neat) 3060, 2944, 1669, 




b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium hexafluorophosphate (39d) 
 
46 mg of light brown solid (58% yield). rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; acetone-d6): δ  11.63 (bs, 1H), 7.84 (s, 1H), 7.71-7.68 (m, 1H), 7.52-7.49 (m, 1H), 
7.21-7.14 (m, 2H), 7.02 (d, J = 8.3 Hz, 1H), 6.42-6.41 (m, 1H), 5.44 (d, J = 16.4 Hz, 1H), 5.32-5.24 (m, 
2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.58 (dd, J = 16.7, 4.6 Hz, 1H), 3.33 (dd, J = 16.9, 0.6 Hz, 1H). 13C-NMR 
(101 MHz; acetone): δ 166.8, 144.5, 140.5, 139.2, 135.7, 134.6, 133.0, 130.2, 128.9, 128.18, 128.07, 
125.9, 122.5, 119.2, 118.3, 112.2, 111.1, 77.6, 62.6, 59.9, 55.34, 55.30, 36.7  MS: calcd for 
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(5aS,10bR)-2-(perfluorophenyl)-9-(o-tolyl)-4,5a,6,10b-tetrahydroindeno[2,1-b][1,2,4]triazolo[4,3-
d][1,4]oxazin-2-ium tetrafluoroborate (39e) 
 
62 mg of light rusty-brown solid (99% yield). rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; aceton-d6): δ 7.58-7.52 (m, 2H), 7.41-7.38 (m, 1H), 7.28-7.26 (m, 3H), 7.16 (dd, J = 
2.5, 0.6 Hz, 1H), 6.45-6.43 (m, 1H), 5.45 (d, J = 16.4 Hz, 1H), 5.32-5.25 (m, 2H), 3.62 (dd, J = 17.0, 5.0 
Hz, 1H), 3.37 (d, J = 17.2 Hz, 1H), 2.20 (s, 3H). 13C-NMR (101 MHz; acetone): δ 151.7, 141.3, 139.4, 
135.4, 135.1, 130.54, 130.35, 129.6, 129.3, 128.2, 127.5, 125.9, 125.4, 124.8, 77.6, 62.6, 60.0, 36.8, 19.6 
MS calcd for C25H17F5N3O+ Expect: 470.41 Found 470.1 IR: (neat) 3059, 1698, 1594, 1550, 1528, 1517, 
1479, 1249, 1074,1002, 858 cm-1.  [α]D23 = -75.79 (c = 1.9, acetone) 
   
 
(5aS,10bR)-9-(4-(tert-butyl)phenyl)-2-(perfluorophenyl)-4,5a,6,10b-tetrahydroindeno[2,1-
b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoroborate (39f) 
 
58 mg of light brown solid (80% yield). rf = 0.15 (50% EtOAc/Hexane) 
1H-NMR (300 MHz; aceton-d6): δ 7.86 (s, 1H), 7.70 (dd, J = 7.8, 0.9 Hz, 1H), 7.58-7.47 (m, 4H), 7.28-
7.14 (m, 1H), 6.42 (s, 1H), 5.44 (d, J = 16.4 Hz, 1H), 5.32-5.25 (m, 2H), 3.59 (dd, J = 17.3, 5.2 Hz, 1H), 
3.37-3.31 (m, 2H), 1.33 (s, 9H). 13C-NMR (101 MHz; acetone): δ 151.7, 140.5, 139.6, 137.4, 135.9, 134.2, 
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59.9, 36.7, 30.7  MS: calcd for C28H23F5N3O Expect: 512.49 Found: 512.2 IR: (neat) 2963, 1595, 1550, 




b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoroborate (39g) 
 
60 mg of light brown solid (80% yield).5 rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-D6): δ  11.29 (br s, 1H), 8.24 (s, 2H), 8.07 (s, 1H), 8.04 (d, J = 0.7 Hz, 1H), 
7.92-7.90 (m, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.31-7.29 (m, 1H), 7.24-7.14 (m, 1H), 6.46 (d, J = 4.2 Hz, 1H), 
5.43 (d, J = 16.4 Hz, 1H), 5.32-5.28 (m, 2H), 3.69-3.63 (m, 1H), 3.39 (d, J = 17.4 Hz, 1H).  13C-NMR (101 
MHz; acetone-D6): δ 151.5, 142.9, 141.9, 137.2, 136.5, 132.0, 131.7, 129.26, 129.06, 128.2, 128.0, 
127.52, 127.50, 127.47, 126.4, 126.2, 123.6, 122.2, 121.01, 120.97, 77.6, 62.5, 60.0, 36.9.  MS calcd for 
C26H13F11N3O+ : 592.38, found: 592.1 (M+). IR: (neat) 3098, 1700, 1596, 1529, 1518, 1378, 1320, 1180, 
1134, 1076, 1004 cm-1.  [α]D23 = -138.52 (c = 2.7, acetone) 
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5	  Alternative purification was used:  Solvent is removed by rotary evaporator.  The crude product is 
dissolved in minimal amount of Et2O and the triazolium salt is precipitated by addition of hexanes.  
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(5aS,10bR)-9-(2,4-difluorophenyl)-2-(perfluorophenyl)-4,5a,6,10b-tetrahydroindeno[2,1-
b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoroborate (39h) 
 
53 mg of light purple solid (65% yield). rf = 0.1 (50% EtOAc/Hexane) 
1H-NMR (400 MHz; acetone-D6): δ  11.23 (br s, 1H), 7.77 (t, J = 0.4 Hz, 1H), 7.61-7.55 (m, 3H), 7.15-7.10 
(m, 2H), 6.42 (d, J = 4.2 Hz, 1H), 5.43 (d, J = 16.4 Hz, 1H), 5.29 (dd, J = 16.3, 0.3 Hz, 1H), 5.26 (d, J = 
4.3 Hz, 1H), 3.64-3.59 (m, 1H), 3.38-3.34 (m, 1H).  13C-NMR (101 MHz; acetone-D6): δ 163.7, 151.7, 
146.3, 140.6, 135.9, 134.2, 132.23, 132.19, 132.14, 132.09, 130.47, 130.43, 129.3, 128.2, 126.2, 125.7, 
124.78, 124.76, 111.97, 111.93, 111.76, 111.72, 104.1, 103.8, 77.5, 62.5, 60.0, 36.8.  MS calcd for 
C24H13F7N3O+ : 492.37, found: 492.1 (M+). IR: (neat) 3648, 3095, 2361, 2341, 1596, 1529, 1516, 1484, 
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To a dry, 2 dram glass vial is added lactam 36 (166mg, 0.62 mmol, 1 equiv.), boronic acid (180 mg, 0.93 
mmol, 1.5 equiv.), Pd(PPh3)2Cl2 (21 mg, 0.03mmol, 0.05 equiv.), and potassium phosphate (263 mg, 1.24 
mmol, 2 equiv.).  An argon atmosphere is introduced, and 3 ml of tetrahydrofuran/water solution (3:1 v/v) 
is added.  The vial is sealed, the cap is wrapped with Teflon tape, and heated at 60 °C for 5 hours.  The 
reaction is cooled to room temperature and diluted with ethyl acetate (2 mL).  The reaction mixture is 
washed with brine (2 x 1 mL) and the organic phase is dried over MgSO4.  The drying agent is filtered off, 
washed with ethyl acetate, and concentrated by rotary evaporator.  The crude product is purified by 
column chromatography, eluting with 50% ethyl acetate/hexane through silica gel.  Isolated 146 mg (70%) 
of a light brown solid. 
 
In a dray, 10 mL round bottom flask, 146 mg of 40 (0.43 mmol, 1 equiv) is dissolved in 3 mL of DCM.  
Trimethyloxonium tetrafluoroborate (63 mg, 0.43 mmol, 1 equiv) is added and the reaction is stirred at 
room temperature for 6 h.  Upon visual disappearance of solids in the reaction mixture, 
pentafluorophenylhydrazine (85 mg, 0.43 mmol, 1 equiv.) is added and the reaction is stirred overnight at 
room temperature.  Product formation is determined by aliquot NMR.  Solvent is removed in vacuo and 1 
ml of triethylorthoformate and 2 ml of chlorobenzene is added.  A reflux condenser is attached and the 
reaction is stirred at 130 °C for 2 days.  The solvent is removed by rotary evaporator and the crude 
product is purified by column chromatography, eluting with 10%MeOH/DCM through silica gel.  Isolated 
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(5aS,10bR)-9-(3-(ethoxycarbonyl)phenyl)-2-(perfluorophenyl)-4,5a,6,10b-tetrahydroindeno[2,1-
b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoroborate (41) 
	  
114	  mg	  of	  red	  solid	  (43%	  yield).	  	  	  rf	  =	  0.2	  (50%	  EtOAc/Hexane)	  
1H-NMR (400 MHz; acetone-d6): δ 11.33 (s, 1H), 8.22 (t, J = 1.7 Hz, 1H), 8.01-7.99 (m, 2H), 7.94-7.91 (m, 2H), 7.76 
(d, J = 7.9 Hz, 1H), 7.59 (t, J = 7.6 Hz, 2H), 6.44 (d, J = 4.0 Hz, 1H), 5.73 (s, 1H), 5.41 (s, 1H), 5.30 (d, J = 16.6 Hz, 
2H), 4.38 (t, J = 7.1 Hz, 2H), 3.65-3.59 (m, 1H), 3.36 (d, J = 17.3 Hz, 1H), 1.37 (t, J = 7.0 Hz, 3H).  13C NMR (101 
MHz; acetone): δ 165.7, 151.6, 146.4, 140.65, 140.59, 139.4, 136.2, 131.6, 131.3, 129.3, 128.6, 128.3, 127.54, 
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APPENDIX 5 




Crystallographic Data for Figure 4.2 
 
X-Ray grade crystals were formed by dissolving the NHC catalyst in minimal Ethyl Acetate and layer with 
heptane in a 1.5 dram vial.  Vial was capped and punctured several times with a syringe needle.  The 








  Table 1.  Crystal data and structure refinement for Rovis175. 
Identification code  Rovis175 
Empirical formula  C18 H11 B F9 N3 O 
Formula weight  467.11 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 7.6458(11) Å a= 90°. 
 b = 10.4929(15) Å b= 90°. 
 c = 22.929(3) Å g = 90°. 
Volume 1839.5(5) Å3 
Z 4 
Density (calculated) 1.687 Mg/m3 
Absorption coefficient 0.169 mm-1 
F(000) 936 
Crystal size 0.384 x 0.276 x 0.260 mm3 
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Theta range for data collection 2.134 to 32.010°. 
Index ranges -9<=h<=10, -13<=k<=14, -34<=l<=23 
Reflections collected 27221 
Independent reflections 5336 [R(int) = 0.0380] 
Completeness to theta = 25.242° 99.9 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5336 / 0 / 289 
Goodness-of-fit on F2 1.032 
Final R indices [I>2sigma(I)] R1 = 0.0384, wR2 = 0.0855 
R indices (all data) R1 = 0.0454, wR2 = 0.0897 
Absolute structure parameter 0.0(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.520 and -0.462 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for Rovis175.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
B(1) 201(3) 4630(2) 8487(1) 19(1) 
C(1) 2876(3) 688(2) 9399(1) 24(1) 
C(2) 2375(3) -280(2) 9031(1) 21(1) 
C(3) 2565(3) -128(2) 8439(1) 18(1) 
C(4) 3237(3) 1000(2) 8218(1) 16(1) 
C(5) 3752(3) 1958(2) 8593(1) 19(1) 
C(6) 3578(3) 1803(2) 9184(1) 24(1) 
C(7) 2122(3) 6637(2) 5996(1) 26(1) 
C(8) 1868(3) 6235(2) 6565(1) 24(1) 
C(9) 1886(3) 4944(2) 6704(1) 18(1) 
C(10) 2181(2) 4073(2) 6262(1) 15(1) 
C(11) 2506(3) 4470(2) 5695(1) 18(1) 
C(12) 2464(3) 5757(2) 5558(1) 24(1) 
C(13) 2103(2) 2634(2) 6269(1) 14(1) 
C(14) 3115(3) 2239(2) 5718(1) 16(1) 
C(15) 2819(3) 3349(2) 5299(1) 20(1) 
C(16) 4391(3) 1293(2) 6769(1) 16(1) 
C(17) 5375(3) 1138(2) 6213(1) 23(1) 
C(18) 2257(3) 1958(2) 7311(1) 16(1) 
F(1) 1109(3) 4493(2) 9000(1) 62(1) 
F(2) 599(3) 3622(2) 8132(1) 53(1) 
F(3) 719(2) 5758(1) 8212(1) 28(1) 
F(4) -1581(2) 4653(1) 8600(1) 37(1) 
F(5) 2081(2) -1064(1) 8082(1) 26(1) 
F(6) 1699(2) -1354(1) 9249(1) 29(1) 
F(7) 2714(2) 541(2) 9971(1) 36(1) 
F(8) 4144(2) 2709(1) 9544(1) 33(1) 
F(9) 4439(2) 3026(1) 8382(1) 25(1) 
N(1) 2899(2) 2026(2) 6779(1) 13(1) 
N(2) 3336(2) 1224(2) 7611(1) 16(1) 
N(3) 4715(2) 790(2) 7277(1) 19(1) 
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O(1) 4954(2) 2186(2) 5843(1) 19(1) 
________________________________________________________________________________ 
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 Table 3.   Bond lengths [Å] and angles [°] for  Rovis175. 
_____________________________________________________  
B(1)-F(2)  1.370(3) 
B(1)-F(1)  1.375(3) 
B(1)-F(4)  1.387(3) 
B(1)-F(3)  1.398(3) 
C(1)-F(7)  1.327(2) 
C(1)-C(2)  1.376(3) 
C(1)-C(6)  1.378(3) 
C(2)-F(6)  1.336(3) 
C(2)-C(3)  1.373(3) 
C(3)-F(5)  1.331(3) 
C(3)-C(4)  1.386(3) 
C(4)-C(5)  1.380(3) 
C(4)-N(2)  1.415(2) 
C(5)-F(9)  1.329(3) 
C(5)-C(6)  1.372(3) 
C(6)-F(8)  1.330(3) 
C(7)-C(8)  1.384(3) 
C(7)-C(12)  1.390(3) 
C(8)-C(9)  1.393(3) 
C(9)-C(10)  1.383(3) 
C(10)-C(11)  1.388(3) 
C(10)-C(13)  1.511(3) 
C(11)-C(12)  1.387(3) 
C(11)-C(15)  1.504(3) 
C(13)-N(1)  1.463(2) 
C(13)-C(14)  1.538(3) 
C(14)-O(1)  1.436(2) 
C(14)-C(15)  1.526(3) 
C(16)-N(3)  1.302(3) 
C(16)-N(1)  1.376(3) 
C(16)-C(17)  1.489(3) 
C(17)-O(1)  1.426(2) 
C(18)-N(1)  1.318(2) 
C(18)-N(2)  1.321(3) 
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Symmetry transformations used to generate equivalent atoms:  
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for Rovis175.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
B(1) 18(1)  16(1) 24(1)  -2(1) 4(1)  1(1) 
C(1) 22(1)  35(1) 15(1)  6(1) 3(1)  8(1) 
C(2) 16(1)  25(1) 23(1)  12(1) 1(1)  2(1) 
C(3) 16(1)  20(1) 19(1)  3(1) -2(1)  2(1) 
C(4) 16(1)  19(1) 14(1)  4(1) 1(1)  4(1) 
C(5) 20(1)  18(1) 18(1)  2(1) 3(1)  4(1) 
C(6) 28(1)  27(1) 16(1)  -3(1) 1(1)  7(1) 
C(7) 24(1)  16(1) 38(1)  6(1) -1(1)  2(1) 
C(8) 22(1)  18(1) 32(1)  -5(1) -1(1)  3(1) 
C(9) 16(1)  18(1) 20(1)  -1(1) 0(1)  2(1) 
C(10) 12(1)  15(1) 18(1)  2(1) -3(1)  1(1) 
C(11) 15(1)  18(1) 19(1)  2(1) -3(1)  0(1) 
C(12) 25(1)  21(1) 26(1)  9(1) -2(1)  1(1) 
C(13) 14(1)  15(1) 13(1)  2(1) -2(1)  0(1) 
C(14) 19(1)  17(1) 14(1)  -1(1) -2(1)  0(1) 
C(15) 23(1)  22(1) 13(1)  1(1) -4(1)  0(1) 
C(16) 16(1)  17(1) 16(1)  1(1) 1(1)  4(1) 
C(17) 24(1)  28(1) 16(1)  5(1) 5(1)  10(1) 
C(18) 17(1)  14(1) 17(1)  2(1) 1(1)  2(1) 
F(1) 54(1)  96(2) 36(1)  26(1) -16(1)  -38(1) 
F(2) 63(1)  25(1) 70(1)  -20(1) 39(1)  -9(1) 
F(3) 21(1)  18(1) 44(1)  7(1) 7(1)  0(1) 
F(4) 19(1)  22(1) 68(1)  13(1) 13(1)  3(1) 
F(5) 29(1)  22(1) 28(1)  1(1) -4(1)  -3(1) 
F(6) 23(1)  32(1) 32(1)  19(1) 0(1)  -2(1) 
F(7) 46(1)  48(1) 15(1)  9(1) 5(1)  4(1) 
F(8) 45(1)  34(1) 19(1)  -10(1) 1(1)  6(1) 
F(9) 35(1)  16(1) 24(1)  1(1) 5(1)  -2(1) 
N(1) 13(1)  14(1) 13(1)  1(1) 0(1)  1(1) 
N(2) 17(1)  16(1) 15(1)  2(1) 3(1)  4(1) 
N(3) 18(1)  22(1) 17(1)  2(1) 3(1)  6(1) 
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APPENDIX 6 
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